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Understanding the molecular, phenotypic, and pathogenic effects of mutations is of 
enormous importance in human disease research and protein engineering. Both create 
a demand for computational methods to leverage the explosion of new sequence data 
and to explore the vast space of possible protein modifications and designs. My study 
in this dissertation demonstrates the value of computational methods in these areas. 
First, I developed a new ensemble method to predict continuous phenotype values as 
well as binary pathogenicity and objectively tested it in CAGI (Critical Assessment of 
Genome Interpretation). In two recent CAGI challenges, the method was ranked third 
in predicting the enzyme activity of missense mutations in NAGLU (N-Acetyl-Alpha-
Glucosaminidase) and second in predicting the relative growth rate of mutated human 
SUMO-ligase in a yeast complementation assay. I also demonstrated the effectiveness 
of the new ensemble method for addressing a key problem limiting the use of current 
  
mutation interpretation methods in the clinic – identifying which mutations can be 
assigned a pathogenic or benign status with high confidence. Next, I characterized 
and compared missense variants in monogenic disease and in cancer. The study 
revealed a  number of properties of  mutations in these two types of diseases, 
including: (a) methods based on sequence conservation properties are as effective for 
identifying cancer driver mutations as they are for monogenic disease mutations;  (b) 
mutations in disordered regions of protein structure play a relatively small role in 
both classes of disease;  (c) oncogenic mutations tend to be on the protein surface 
while tumor suppressors are concentrated in the core; (d) a large fraction of tumor 
suppressors act by destabilizing protein structure and (e)  mutations in passenger 
genes display a surprisingly high level of deleteriousness. Finally, I applied 
computational methods to screen for appropriate mutations to enhance the 
thermostability of a catalytic domain of PlyC. This bacteriophage-derived endolysin 
has been demonstrated to have antimicrobial potential but its potential use is limited 
by its inherent thermosuseptibility. To prioritize stabilizing mutations, I conducted a 
rapid exhaustive survey of point mutations followed by validation using protein 
modeling and expert knowledge. The approach yielded three stabilizing mutants 
experimentally verified by our collaborators, with one particularly successful in terms 
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Chapter 1: Introduction 
 
1.1 Missense variants and human diseases 
1.1.1 The landscape of human mutations 
DNA mutations spontaneously occur at very low frequency due to replication, repair 
and mitotic error. They can also result from exogenous and endogenous factors such 
as chemicals, ultraviolet light, ionizing radiation, oxygen free radicals, and viruses.  
As a consequence, mutations inevitably accumulate in both germ cells and somatic 
cells in spite of the high fidelity molecular machinery for replicating and repairing 
DNA. There are many types of genetic variations including SNVs (single nucleotide 
variants), indels (insertions and/or deletions), CNVs (copy number variations), 
chromosome rearrangements, and large-scale events (e.g. aneuploidy, 
chromothripsis). In terms of the protein translation, SNVs can be synonymous (no 
amino acid change), or nonsynonymous, including missense that alters amino acids, 
and nonsense that leads to premature termination. Non-coding SNVs can affect 
splicing, alter expression and other regulatory processes, or locate at intergenic 
regions with uncertain roles. The vast majority (96%) of genetic variations observed 
in populations are SNVs, although the very few structure variations (large indels, 
CNVs, chromosome rearrangements) affect more base pairs (1000 Genomes Project 






Advances in next-generation sequencing technologies (Reuter, Spacek, & Snyder, 
2015; Shendure & Ji, 2008; Soon, Hariharan, & Snyder, 2013) have generated 
sequence data for tens of thousands of genomes and exomes and that has led to a 
deepening of our understanding of the landscape of human mutations. For germline 
mutations (mutations that occur in the germ cells), it is estimated that each individual 
human carries 1~5 million genetic variants in the whole genome compared with the 
reference genome (1000 Genomes Project Consortium et al., 2015; Roach et al., 
2010), out of which 30~70 are de novo point mutations compared with the parents 
(Francioli et al., 2015). Although on average only about 0.3% of SNPs (single 
nucleotide polymorphisms) observed in one genome are nonsynonymous (and 0.3% 
synonymous, 13% regulatory, and 47% in intron), there are ~10,000 nonsynonymous 
SNVs in each genome when compared with the reference genome (1000 Genomes 
Project Consortium et al., 2015; Ng et al., 2008). On top of these, through trillions of 
cell divisions from early development to adulthood, a substantial number of somatic 
mutations (mutations that occur in the somatic cells) accumulate over time. For 
instance, by middle age, thousands of point mutations may have accumulated in the 
sun-exposed skin cells (Martincorena et al., 2015). As another example, it is roughly 
estimated that there are totally a billion independent mutations accumulated in the 
whole intestinal epithelium of a 60-year-old individual (Lynch, 2010). Cancer cells in 
an individual typically carry various numbers (1000 ~20,000) of somatic point 
mutations, out of which from 10 to as many as 1000 are nonsynonymous (Vogelstein 






The mutation rates of germline SNVs has been estimated as between ~1.0  10-8 to 
2.2  10-8 per base pair (bp) per generation, varying depending on the approach (high 
penetrant Mendelian disease (Lynch, 2010), Phylogenetic analysis (Chimpanzee 
Sequencing and Analysis Consortium, 2005), or whole genome sequencing of 
pedigrees (Ségurel, Wyman, & Przeworski, 2014). It has also been reported to vary 
by more than 100-fold within the genome across individuals (Michaelson et al., 
2012). Germline SNVs tend to be enriched in certain sequence compositions, 
especially at CpG dinucleotides (Hwang & Green, 2004). The mutation rates of 
germline mutations in coding regions are strongly constrained by the expression level 
of genes (Drummond, Raval, & Wilke, 2006; Drummond & Wilke, 2008). The 
mutation rate is also affected by sex and parental age in that de novo point mutations 
among offspring are predominantly related to paternal age (Kong et al., 2012) and 
chromosomal nondisjunction errors are mainly affected by maternal age (Sherman et 
al., 1994). Fewer studies have estimated the mutation rates for other types of variants 
partially because it is technically challenging (Shendure & Akey, 2015). As an 
example, it is estimated that 2.94 small indels (≤ 20 bp) and 0.16 structural variants (> 
20 bp) occur per generation (Kloosterman et al., 2015). The estimated mutation rate 
of somatic mutations is around one order of magnitude higher than germline 
mutations (Lynch, 2010). It dramatically varies across cancer types and individuals 
by up to two orders of magnitude (Martincorena & Campbell, 2015; Vogelstein et al., 
2013). On a fine scale, the mutation rates in somatic cells vary depending on 
environmental factors and impaired DNA replication or repair (Shendure & Akey, 





organization (Martincorena & Luscombe, 2013; Schuster-Böckler & Lehner, 2012; 
Shendure & Akey, 2015). 
 
1.1.2 Human diseases and their genetic basis 
There are three major types of human diseases that closely link to genetic variations, 
monogenic disease (or Mendelian disease), complex trait disease, and cancer. The 
monogenic diseases are usually caused by mutations in a single gene or one of a few 
disease genes. They can follow either a dominant or recessive inheritance pattern and 
are mostly rare. For example, one of the lysosomal storage diseases, Sanfilippo 
syndrome IIIB is caused by mutations in NAGLU gene. The disease is autosomal 
recessive with a reported birth incidence of 0.28-4.1 per 100,000 (Valstar, Ruijter, 
van Diggelen, Poorthuis, & Wijburg, 2008). To date, more than 7000 monogenic 
diseases have been catalogued in the Online Mendelian Inheritance in Man (OMIM) 
database (http://omim.org/). Despite the very low incidences of individual monogenic 
diseases, the birth prevalence of all monogenic diseases in industrialized countries 
was estimated to be 3.6 per 1,000 newborns (Baird, Anderson, Newcombe, & Lowry, 
1988). This number is even higher in the developing countries. Disease-causing genes 
have been identified for more than half of the rare monogenic diseases (Boycott, 
Vanstone, Bulman, & MacKenzie, 2013). The Human Gene Mutation Database 
(HGMD) is a major database of monogenic disease-related genes and mutations. 
Currently, it includes over 203,000 unique gene lesions in over 8000 genes for 
inheritable disease collected from literature (Stenson et al., 2017). 56% of these 





higher fraction of rare monogenic diseases, this proportion is about 60% (Stenson et 
al., 2003). 
 
Complex trait diseases have a higher rate of occurrence than monogenic diseases. A 
single complex trait disease can have incidence and prevalence similar to or more 
than all monogenic diseases combined. For example, Crohn’s disease affects about 
two million people in North America (Molodecky et al., 2012). The number is 5.3 
million for Alzheimer’s disease (Alzheimer’s Association, 2015). Globally, diabetes 
may affect 439 million adults by 2030 (Shaw, Sicree, & Zimmet, 2010). Unlike 
monogenic diseases, up to hundreds of loci in the genome may contribute to a single 
complex trait disease (de Lange et al., 2017). Variants in many of these loci only 
make a small contribution to a disease phenotype. Complex trait diseases are also 
heavily affected by environmental and behavioral factors. For many, the relevant 
genes and variants are still not clear. Much information has been obtained by the 
genome-wide association studies (GWAS), which captures disease-associated 
common SNPs using microarray technology. By including several thousand 
individuals with and without diseases, more than 50,000 unique SNP-trait 
associations have been discovered in more than 2,500 studies (GWAS catalog, 
https://www.ebi.ac.uk/gwas/). Through these associated loci, disease-causing 
mechanism SNPs may sometimes be imputed. It has been shown that missense 
mutations also play an important role in complex trait diseases (Kryukov, 






Cancers are diseases where cells escape constraints on growth, and potentially invade 
other parts of the body. Most cancers are caused by somatic mutations, while certain 
germline mutations can increase the risk of an individual developing the disease. 
There have been sequencing studies at the level of exomes and increasingly complete 
in more than 30 types of cancers. The sequence data are available in several major 
databases including the Cancer Genome Atlas (TCGA, 
https://cancergenome.nih.gov/), Catalogue of Somatic Mutations in Cancer 
(COSMIC, http://cancer.sanger.ac.uk/cosmic), and the International Cancer Genome 
Consortium (ICGC, http://icgc.org). To date, more than 500 genes have been 
catalogued by the Cancer Gene Census (CGC, http://cancer.sanger.ac.uk/census) as 
causal genes. Although dramatic variations exist across individuals and across cancer 
types, there are on average 33 to 66 mutated genes with altered functions in a tumor. 
86% of the mutations in these genes are missense, 7% are nonsense, and 1.6% are at 
splice sites or close to coding regions (Vogelstein et al., 2013). It was also reported 
that cancer types can be divided into two classes based on whether dominated by 
SNVs or by CNVs (Ciriello et al., 2013). At one end of the spectrum, a single tumor 
can carry thousands of mutations if the mismatch repair (Gryfe & Gallinger, 2001) or 
proofreading machinery (Palles et al., 2013) is damaged. At the other end of the 
spectrum, on average pediatric tumors and leukemias may just carry 9.6 point 
mutations per tumor (Vogelstein et al., 2013). In contrast to this large variation, it is 
estimated that most cancer types have less than 5 key point mutations (real driver) per 
tumor (Sabarinathan et al., 2017). At present, there are no established quantitative 





cancer types is closely related to the number of cell divisions in the corresponding 
tissue (Tomasetti, Li, & Vogelstein, 2017), implying that driver incidence is largely 
determined by this factor. In general, there are two types of cancer driver genes, 
oncogenes that acquire gain-of-functions through mutations, and tumor suppressor 
genes that lose function through mutations. Driver mutations in well-studied 
oncogenes and tumor suppressor genes show obvious different patterns, with 
mutations recurrently happening at the same positions (hotspots) in oncogenes, and 
more evenly distributed through tumor suppressor genes (Vogelstein et al., 2013). 
One feature of cancer mutations is that mutations in cancer driver genes can also be 
passenger mutations. For example, among mutations in the APC protein, only those 
within the N-terminus are drivers, whereas those within the C-terminus are 
passengers (Vogelstein et al., 2013). 
 
1.2 Computational interpretation of missense mutations 
1.2.1 General mutation interpreting methods 
The advent of massive genome and exome sequencing creates a major demand for 
reliable bioinformatics tools to interpret and prioritize the genetic variations that have 
functional consequences. New computational approaches have been developed and 
applied to genetic variations in general (Cooper & Shendure, 2011; Peterson, 
Doughty, & Kann, 2013) and in cancer (Gonzalez-Perez, Mustonen, et al., 2013). In 
principle, a mutation interpretation method can identify the consequence of a given 





deleteriousness to the organism, and 3) pathogenicity (whether or not causing disease) 
(Shendure & Akey, 2015). While these three tasks are related, the majority of current 
computational methods measure deleteriousness using evolution information. For 
missense mutations, methods compare a mutation substitution with residues found in 
homologous protein sequences and variants within the human population under the 
assumption that conserved positions or the absence of population variants indicate 
stronger constraints from purifying selection. In this sense, these methods make use 
of fitness impact as a surrogate for pathogenicity (Calabrese, Capriotti, Fariselli, 
Martelli, & Casadio, 2009; Choi, Sims, Murphy, Miller, & Chan, 2012; Chun & Fay, 
2009; Katsonis & Lichtarge, 2014; Kircher et al., 2014; Lichtarge, Bourne, & Cohen, 
1996; Ng & Henikoff, 2003; Niroula & Vihinen, 2016; Schwarz, Rödelsperger, 
Schuelke, & Seelow, 2010; Thomas et al., 2006; Yue & Moult, 2006). The similar 
principle can be applied to methods that address non-coding variations, where 
nucleotide sequence profiles replace protein sequence profiles (Cooper et al., 2005; 
Pollard, Hubisz, Rosenbloom, & Siepel, 2010). Some methods also incorporate 
physical-chemical (e.g. amino acid properties), structure information (e.g. secondary 
structure element and solvent accessibility), and functional annotations (Adzhubei et 
al., 2010; Baugh et al., 2016; Carter, Douville, Stenson, Cooper, & Karchin, 2013; 
Folkman, Stantic, Sattar, & Zhou, 2016; B. Li et al., 2009). A few methods adopt an 
ensemble approach by incorporating outcomes from multiple other methods 
(Capriotti, Altman, & Bromberg, 2013; González-Pérez & López-Bigas, 2011; 
Ioannidis et al., 2016; Olatubosun, Väliaho, Härkönen, Thusberg, & Vihinen, 2012). 





modeling to infer impact on protein thermostability (Redler, Das, Diaz, & Dokholyan, 
2016; Yue, Li, & Moult, 2005). These methods are designed to detect when a 
mutation destabilizes protein three-dimensional structure, and so have more limited 
scope than sequence methods. Most methods use supervised machine learning and 
require a training classifier such as random forest (Carter et al., 2013; B. Li et al., 
2009; Niroula, Urolagin, & Vihinen, 2015), neural network (Hecht, Bromberg, & 
Rost, 2015), or support vector machines (SVMs) (Calabrese et al., 2009; Kircher et 
al., 2014; Yue & Moult, 2006). A few methods rely on direct measures of certain 
properties (e.g. evolutionary), and do not require training (Choi et al., 2012; Chun & 
Fay, 2009; Lichtarge et al., 1996; Ng & Henikoff, 2003; Thomas et al., 2006). 
 
1.2.2 Cancer-specific methods 
Although originally not intended for that purpose, most methods mentioned above 
can be applied to interpret the impact of cancer somatic mutations, as will be 
discussed later in Chapter 3. In addition, there are computational methods specifically 
developed for interpreting cancer data. One class of methods aims to prioritize cancer 
driver genes using mainly three types of information (Hofree et al., 2016): 1) SNV 
recurrence, 2) SNV molecular impact, and 3) SNV spatial clustering. Some only rely 
on SNV molecular impact (Gonzalez-Perez, Deu-Pons, & Lopez-Bigas, 2012) or 
SNV clustering (Tamborero, Gonzalez-Perez, Perez-Llamas, et al., 2013; Tamborero, 
Gonzalez-Perez, & Lopez-Bigas, 2013). Others combined all three types of 
information (Dees et al., 2012; Khurana et al., 2013; Lawrence et al., 2013). The 





information to that in the general mutation interpreting methods (Carter et al., 2009; 
Gonzalez-Perez et al., 2012; Joshua S Kaminker, Zhang, Watanabe, & Zhang, 2007; 
Mao et al., 2013; Reva, Antipin, & Sander, 2011; Shihab, Gough, Cooper, Day, & 
Gaunt, 2013; Yue et al., 2010). Very few computational methods were designed to 
address other types of somatic variations (e.g. CNV) (Mermel et al., 2011), or 
mutated gene subnetworks (Leiserson et al., 2015). There is also one method that 
combines driver gene discovery and mutation analysis into a single pipeline 
(Gonzalez-Perez, Perez-Llamas, et al., 2013). 
 
1.2.3 Critical assessment of contemporary methods 
There are very few studies that independently assess the performance of the current 
mutation interpretation methods (Gnad, Baucom, Mukhyala, Manning, & Zhang, 
2013; Martelotto et al., 2014). In order to have an objective assessment of the state of 
the art, John Moult and Steven Brenner started the Critical Assessment of Genome 
Interpretation (CAGI, https://genomeinterpretation.org/) (Hoskins et al., 2017) as 
community-wide experiments to test a variety of mutation and genome interpretation 
methods. In analogy to the Critical Assessment of Structure Prediction (CASP) 
(Moult, Fidelis, Kryshtafovych, Schwede, & Tramontano, 2016), CAGI strictly 
separates predictors, data providers, and assessors. Participants are asked to predict 
particular phenotypes, given genetic variant information. Meanwhile, the 
corresponding experimental results are not released until all participants have 
submitted their predictions, thus these are bona fide blind predictions. Independent 





The challenges in CAGI cover a wide range of prediction problems and datasets. For 
example, in the latest CAGI round (CAGI4), there were datasets of germline and 
somatic mutations in exomes, whole genomes, clinical gene panels and individual 
genes in the context of rare monogenic disease,  complex trait disease, and cancers. 
Challenges also included identification of eQTL causal SNPs and deep mutation 
scanning data. Most missense mutation analysis methods report a binary assignment 
of deleterious or not deleterious. Therefore, two CAGI challenges, NAGLU and 
SUMO-ligase (Zhang et al., 2017), are of particular interest in this dissertation in that 
they request predictions of continuous activity values. Initially motivated by this, I 
developed an ensemble approach, and further extended its application to both binary 
pathogenic prediction and estimation of the subset of mutations with high-reliability 
assignments.  
 
The human NAGLU gene encodes N-acetyl-glucosaminidase, an enzyme that 
catalyzes the cleavage of the glucosaminoglycan chain of heparin sulfate in 
lysosomes. It is one of four genes (Valstar et al., 2008) in which mutations may cause 
one of the four types of Mucopolysaccharidosis III or Sanfilippo Syndrome 
(Sanfilippo, Podosin, Langer, & Good, 1963), a severe neurological disease. The 
human NAGLU protein exists as a homo-trimer in vivo. The three-dimensional 
structure of the protein is available from a recent patent (US08775146B2, 2014) 
(Figure 1-1). The CAGI challenge was based on a set of 165 rare missense NAGLU 
mutations found in the European population samples of the ExAC exome database 





company providing the challenge data, introduced each mutation into a human cell 
line via a plasmid construct, and after a period of cell growth, measured NAGLU 
enzyme activity in the cell lysate. 
Figure 1-1. Structure of the human NAGLU homo-trimer, based on the crystal 
structure reported in patent USPTO US08775146B2. The three identical NAGLU 
monomers (green, cyan, and magenta) form a symmetrical complex. The 






Figure 1-2. Structure of human UBE2I (green) in complex with SUMO (cyan), E3 
ligase (yellow), and the substrate RANGAP1 (magenta). The UBE2I catalytic site is 
indicated by the red circle. PDB: 3UIP (Gareau, Reverter, & Lima, 2012) 
 
The human UBE2I gene encodes the SUMO E2 ligase, an enzyme that catalyzes the 
attachment of a range of target substrate proteins to SUMO (Geiss-Friedlander & 
Melchior, 2007) (See Figure 1-2 for one example). In the challenge, over 6,000 





S. cerevisiae cells carrying a temperature-sensitive UBC9 gene (encoding the 
corresponding yeast SUMO-ligase (Weile et al., 2017). The relative abundance of 
cells carrying each mutant gene was deduced from high-throughput sequencing of the 
barcodes, following 48 hours of cell growth. 
 
1.3 Engineering through protein design 
1.3.1 Advances in structure modeling methods 
The goal of computational protein design is to find a protein sequence that folds into 
an appropriate three-dimensional structure and so confers a desired new property or 
function such as a de novo fold, enhanced protein thermostability, altered binding 
affinity or specificity of protein-ligand and protein-macromolecule interaction, altered 
enzymatic activity, among others. Protein design methods typically involve a process 
in which an energy function and a conformational search process are used to assess 
the impact of some particular missense mutations in a certain structure context, which 
is, in some sense, comparable to the structure based mutation interpreting tools. 
However, unlike the latter, protein design also involves a process to search for 
optimal mutations in a large sequence space. In full protein design and in mutation 
selection, experimental validation plays a key role. 
 
Protein design methods arose out of protein structural modeling methods, for 
example, the RosettaDesign protocol of the Rosetta programs (B Kuhlman & Baker, 





improvements have been made to computational protein modeling algorithms 
(Samish, 2017). A few examples: the use of a set of discrete rotamers and conformers 
instead of treating amino acid side chain conformations in a continuous three-
dimensional space facilitates the efficacy of describing protein structures (Dunbrack, 
2002). The inclusion of flexible protein backbone sampling methods improves the 
accuracy of the structure modeling (Ollikainen, Smith, Fraser, & Kortemme, 2013). 
The invention of a knowledge-based approach to reassemble proteins from known 
high-resolution structural fragments has greatly boosted the efficiency and accuracy 
of protein structure prediction (B Kuhlman & Baker, 2000). To search for the global 
minimum energy conformation (GMEC), both deterministic methods (e.g. linear 
programming, and dead-end elimination, DEE) and stochastic methods (e.g. Monte 
Carlo Markov Chain, MCMC) have been adopted (Samish, 2009). For protein design, 
improvements were also seen in terms of the design strategy, such as the inclusion of 
negative design and the Cluster Expansion method (Grigoryan, Reinke, & Keating, 
2009). Protein design is a relatively new field, and there are still many challenges, 
such as loop design. 
 
1.3.2 Application of computational protein design methods 
Computational protein design has been applied to a broad range of protein 
engineering problems. For example, it was used to improve the thermostability of 
human acetylcholinesterase by 20C (Goldenzweig et al., 2016) and increased the 





49C to 99C (Shah et al., 2007), to alter protein-protein binding specificity 
(Grigoryan et al., 2009), to design protein based lysozyme inhibitor (Procko et al., 
2013), to design pH-dependent protein binding specificity (Strauch, Fleishman, & 
Baker, 2014), and to improve antibody affinity (Lippow, Wittrup, & Tidor, 2007). 
More prominently, computation protein design methods have successfully designed 
proteins with novel folds that do not exist in nature (Brian Kuhlman et al., 2003; 
Xiong et al., 2014), a small stable vaccine to induce potent neutralizing antibodies 
(Correia et al., 2014), and enzymes with new activity (Jiang et al., 2008; 
Röthlisberger et al., 2008; Siegel et al., 2010). 
 
1.3.3 Rosetta and FoldX 
The Rosetta program (Das & Baker, 2008) was developed by David Baker and many 
collaborators. The method consists of two major algorithms (B Kuhlman & Baker, 
2000; Rohl et al., 2004): 1) Monte Carlo sampling of peptide fragment conformation 
space shaped by local contacts to reduce the conformational search problem 2) 
Searching for the optimal protein conformation using an energy function of mixed 
physical and statistical terms. It now includes dozens of modeling and design 
protocols tailored to different tasks. Particularly, the Rosetta ddG application predicts 
the change of protein folding free energy change (ΔΔG) induced by point mutations 
(Kellogg, Leaver-Fay, & Baker, 2011). Another program, FoldX (Guerois, Nielsen, & 
Serrano, 2002; Schymkowitz, Borg, et al., 2005; Schymkowitz, Rousseau, et al., 





der Waals interactions, hydrogen bonding, electrostatic and solvation, and statistical 
energy terms computed from observations in the database of known protein 
structures. Given a point mutation, FoldX uses a fixed backbone modeling process 
that can rapidly estimate the impact of a mutation on the folding free energy.  
 
1.3.4 PlyC as a potential antimicrobial 
Endolysins (phage lysins) are bacteriophage peptidoglycan hydrolases (Nelson, 
Schuch, Chahales, Zhu, & Fischetti, 2006). Purified PlyC proteins can be applied to 
lyse the cell wall of susceptible streptococci both in vitro and in vivo with a superior 
activity compared to other endolysins (Nelson, Loomis, & Fischetti, 2001). The 
protein structure of PlyC is unique in that it consists of eight identical PlyCB 
monomers forming an octameric ring structure as the cell wall binding domain, and a 
PlyCA subunit as the catalytic domain. Two domains of PlyCA, N-terminal glycosyl 
hydrolase (GyH) and C-terminal cysteine, histidine-dependent 
amidohydrolase/peptidase (CHAP), catalyze distinct reactions synergistically. The 
PlyCB octamer and PlyCA are connected via a helical docking domain (McGowan et 
al., 2012). Although PlyC is a potential antimicrobial, the PlyCA CHAP domain is 
very thermal unstable, which could limit its shelf life. 
 
1.4 Overview 
The dissertation is organized as follows. In Chapter 2, I first review the previous 





an introduction of the two CAGI challenges. I then present the results and post 
analysis of the ensemble methods for prediction of continuous activity, binary 
assignment, and estimation of reliability. In Chapter 3, I describe the current picture 
of missense somatic mutations in cancers, the current computational methods, and 
issues in identifying cancer driver genes and driver mutations. I then present the 
results of characterizing and comparing missense variants in monogenic diseases and 
cancer in light of a better understanding of cancer driver mutations and their effects. 
In Chapter 4, I describe the computational and experimental approaches to engineer 
PlyC CHAP domain thermostability. I then present the successful mutation and the 
experimental validation results. In Chapter 5, I summarize the conclusions of the 
three projects and then look into future prospects for improving computational 











Chapter 2: Ensemble variant interpretation methods to predict 
enzyme activity and assign pathogenicity in the CAGI4 
NAGLU (Human N-acetyl-glucosaminidase) and UBE2I 
(Human SUMO-ligase) challenges 
 
Published:  
Yin Y, Kundu K, Pal LR, Moult J. 2017. Ensemble variant interpretation methods to 
predict enzyme activity and assign pathogenicity in the CAGI4 NAGLU (Human N-
acetyl-glucosaminidase) and UBE2I (Human SUMO-ligase) challenges. Human 
Mutation 38(9):1109-1122. 
My contribution: computational experiments and data analysis 
 
2.1 Abstract 
CAGI (Critical Assessment of Genome Interpretation) conducts community 
experiments to determine the state of the art in relating genotype to phenotype. Here 
we report results obtained using newly-developed ensemble methods to address two 
CAGI4 challenges: enzyme activity for population missense variants found in 
NAGLU (Human N-acetyl-glucosaminidase) and random missense mutations in 
Human UBE2I (Human SUMO E2 ligase), assayed in a high throughput competitive 
yeast complementation procedure. The ensemble methods are effective, ranked 2nd for 





However, in common with other methods used in CAGI, there are large discrepancies 
between predicted and experimental activities for a subset of variants. Analysis of the 
structural context provides some insight into these. Post-challenge analysis shows the 
ensemble methods are also effective at assigning pathogenicity for the NAGLU 
variants. In the clinic, providing an estimate of the reliability of pathogenic 
assignments is key. I have also used the NAGLU dataset to show that ensemble 
methods have considerable potential for this task, and are already reliable enough for 
use with a subset of mutations. 
 
2.2 Introduction 
The vast quantities of data generated by the high-throughput genotyping and next-
generation sequencing technologies (Reuter et al., 2015; Soon et al., 2013) have 
created a major demand for reliable methods of interpreting the phenotypic 
significance of genetic variation, particularly as it relates to human disease. Among 
various types of genetic variation, missense single nucleotide polymorphisms (SNPs) 
and missense rare mutations in coding regions are of particular interest because of the 
major role these play in monogenic disease (Stenson et al., 2014), complex trait 
disease (Kryukov et al., 2007; Pal & Moult, 2015), and cancer (Shi & Moult, 2011; 
Wood et al., 2007). 
 
Many computational methods have been developed to identify the relevance of 
missense variants to disease (Peterson et al., 2013). Most of these methods make use 





likely fitness impact of an amino acid substitution, assumed to be related to disease 
relevance (Calabrese et al., 2009; Choi et al., 2012; Chun & Fay, 2009; Katsonis & 
Lichtarge, 2014; Kircher et al., 2014; Lichtarge et al., 1996; Ng & Henikoff, 2003; 
Niroula et al., 2015; Schwarz et al., 2010; Thomas et al., 2006; Yue & Moult, 2006). 
A few make use of three-dimensional structure information, particularly to infer any 
thermodynamic destabilization of the structure (Redler et al., 2016; Yue et al., 2005), 
assuming that decreased protein activity implies a relationship to disease. Some 
methods combine both sequence and structure information (Adzhubei et al., 2010; 
Baugh et al., 2016; Carter et al., 2013; Folkman et al., 2016; Hecht et al., 2015; B. Li 
et al., 2009). Methods usually use supervised machine learning such as random forest 
(Carter et al., 2013; B. Li et al., 2009; Niroula et al., 2015), neural network (Hecht et 
al., 2015) and support vector machines (Calabrese et al., 2009; Kircher et al., 2014; 
Yue & Moult, 2006), or models that do not need training (Choi et al., 2012; Chun & 
Fay, 2009; Lichtarge et al., 1996; Ng & Henikoff, 2003; Thomas et al., 2006). 
 
Missense analysis methods have usually been evaluated by benchmarking against 
databases of known monogenic disease mutations and presumed benign species or 
population variants, and there have been very few independent tests. Critical 
Assessment of Genome Interpretation (CAGI), conducts community-wide 
experiments to test these and other genome interpretation methods. CAGI participants 
are provided genetic variant information and asked to predict phenotypic 
consequences. Independent assessors then evaluate the results. The experiments are 





know the identity of the participants. In the most recent CAGI round, CAGI4 
(http://genomeinterpretation.org), there were two missense variant interpretation 
challenges: the NAGLU challenge (https://genomeinterpretation.org/content/4-
NAGLU) and the SUMO-ligase challenge 
(https://genomeinterpretation.org/content/4-SUMO_ligase). Here we report our 
results for these. 
 
NAGLU (MIM# 609701) encodes Human N-acetyl-glucosaminidase, an enzyme 
involved in the heparan sulfate degradation process, and is one of four (Valstar et al. 
2008) lysosomal enzymes in which mutations may result in one of four corresponding 
types of Sanfilippo Syndrome (Sanfilippo et al. 1963). Mutations in NAGLU protein 
cause a rare neurological disease, Mucopolysaccharidosis IIIB or Sanfilippo B 
disease (O’Brien 1972; von Figura and Kresse 1972; Valstar et al. 2008). The 
NAGLU challenge utilized in vitro enzyme activity data for a set of 165 rare 
population missense mutations extracted from the ExAC exome database (60,706 
individual genomes) (Lek et al., 2016), omitting 24 known disease mutations. CAGI 
challenge participants were asked to quantitatively predict the enzymatic activity of 
each mutant relative to that of the wild-type enzyme. A unique feature of the NAGLU 
dataset is that it represents the distribution of protein function of rare variants present 
in a population. To our knowledge, this is the first test of this type for current 
missense analysis methods, and more relevant to variants encountered in the clinic 






UBE2I (MIM# 601661) encodes the human small ubiquitin-like modifier proteins 
conjugating protein (SUMO E2 ligase) that catalyzes the covalent attachment of 
SUMO to a range of target proteins. The CAGI challenge data provider had generated 
a library of over 6,000 human SUMO-ligase UBE2I clones expressing nearly 2,000 
unique missense mutations in various combinations. The competitive growth rate of 
each clone was deduced from deep sequencing of a yeast-based complementation 
system. CAGI participants were asked to predict the relative competitive growth rates 
of yeast cells carrying three different sets of random mutations. Unlike the NAGLU 
challenge, where enzyme activity is known to be directly related to pathogenicity 
(von Figura & Kresse, 1972), the relationship between SUMO-ligase function and 
fitness is complicated by two factors – the multiple regulator and target proteins that 
interact with SUMO-ligase (Geiss-Friedlander & Melchior, 2007), and the fact that 
the human SUMO-ligase was substituted for the native enzyme in yeast cells. These 
factors make this a complex system from the point of view of interpreting the CAGI 
results. Many similar high throughput mutational scans are now being undertaken, so 
it is of interest to use the CAGI experiment to begin to probe the strengths and 
limitations of this approach, both generally, and as a basis for CAGI challenges. 
 
All submitted predictions in each challenge were evaluated by independent assessors, 
one for each challenge. Results reported here were ranked 2nd among 9 groups with 
16 submissions for the SUMO-ligase challenge and 3rd among 10 groups with 17 






Most missense analysis methods assign each variant as either deleterious or benign. 
An unusual feature of both the NAGLU and SUMO-ligase challenges is that they 
require prediction of a continuous variable, in one case relative enzyme activity, and 
in the other, relative yeast growth rate. In other words, the challenges require a 
regression predictor rather than a classification predictor. To address this requirement, 
I made use of an ensemble approach, combining binary predictions or associated 
confidence scores from up to eleven different methods. In a number of fields, 
ensemble methods that combine results from multiple individual methods have 
proven effective (Abeel, Helleputte, Van de Peer, Dupont, & Saeys, 2010; Dietterich, 
2000; Moult, 2005). A number of missense ensemble predictors, for example 
CONDEL (González-Pérez & López-Bigas, 2011), PONP (Olatubosun et al., 2012), 
Meta-SNP (Capriotti et al., 2013) and most recently REVEL (Ioannidis et al., 2016) 
have also been developed for the more usual task of binary classification, but as far as 
we are aware, this is the first use for quantitative prediction of missense impact. 
 
I also performed several post-challenge analyses on the NAGLU dataset, examining 
the usefulness of structure information for identification of deleterious mutations and 
comparing the performance of the new ensemble method with other missense 
methods for binary classification. In the clinic, a major concern is not just to have an 
accurate predictor of pathogenicity, but also to assign a reliable probability that an 
assignment of pathogenic or benign is correct. The NAGLU challenge data set 
provided an opportunity for testing methods of assigning such probabilities on a 






2.3.1 Challenge data and benchmark data 
The challenge set of 165 NAGLU rare population missense mutations was provided 
by Jonathan H. LeBowitz (BioMarin). The SUMO-ligase CAGI challenge set was 
generated by the Fritz Roth lab using a competitive yeast complementation growth 
assay (Weile et al., 2017). Three sets of UBE2I (SUMO-ligase) mutations were 
provided – 1) a reliable (multiple measurements) set of 219 single missense 
mutations, 2) a less reliable set of 463 single missense mutations and 3) a set of 4427 
double or more mutations per clone. The experimental NAGLU enzyme activity data 
and the SUMO-ligase yeast growth data were not released to CAGI participants until 
all predictions had been submitted. In addition, we also collected 90 NAGLU known 
disease-related variants from HGMD (Stenson et al., 2014), together with the 278 
interspecies variants, as a benchmark set. 
 
2.3.2 Data for training predictors of continuous activity 
Methods training for both NAGLU enzyme activity and SUMO-ligase growth rates 
required data that are also on an appropriate continuous scale of biological activity (as 
opposed to the more usual pathogenic/benign classification). For this purpose, a set of 
enzyme activity data for 92 human Phenylalanine hydroxylase (PAH) variants from 
(http://www.biopku.org/pah/) was used, supplemented by a set of 139 PAH 
interspecies variants (identified by comparing the human sequence with those of 





sequence identities higher than 80%), assumed to have full activity. I also searched 
the literature for high throughput mutation datasets that might be appropriate for use 
as training data. Only one of these appeared suitable, a set of cell growth rate data for 
yeast ubiquitin (UBI4) mutations (Roscoe, Thayer, Zeldovich, Fushman, & Bolon, 
2013). In practice, methods trained on these data performed poorly, and so its use was 
discontinued. 
 
2.3.3 Combining multiple missense analysis methods to predict relative protein activity 
For the ensemble methods, up to eleven missense analysis methods were used: 
Polyphen-2 (Adzhubei et al., 2010), SIFT (Ng & Henikoff, 2003), SNPs3D Profile 
(Yue & Moult, 2006), CADD (Kircher et al., 2014), Panther (Thomas et al., 2006), 
PON-P2 (Niroula et al., 2015), SNAP2 (Hecht et al., 2015), PROVEAN (Choi et al., 
2012), VEST3 (Carter, Douville, Stenson, Cooper, & Karchin, 2013), LRT (Chun & 
Fay, 2009) and MutationTaster (Schwarz et al., 2010). The dbNSFP2.9 database (X. 
Liu, Jian, & Boerwinkle, 2013) was used to obtain CADD, PROVEAN, LRT, VEST3 
and MutationTaster results. SNPs3D Profile results were obtained using the 
standalone in-house software. Results of other methods were obtained from the 
corresponding web-servers. 
 
Binary predictions and associated scores were collected when both were available. 
Polyphen-2 ‘Probably damaging’ and ‘Possibly damaging’ were merged as a 
deleterious assignment. The MutationTaster deleterious set was compiled by 





categories. Four methods (CADD, SNPs3D profile, Panther, and VEST3) didn’t 
directly report binary assignments. The recommended threshold score of 15 was used 
for CADD and the standard score threshold of zero was used for SNPs3D profile.  A 
‘deleterious’ score of 0.5 and a score of 0.77 were chosen as the cutoffs for Panther 
and VEST3 respectively, the values at which the distribution curves of deleterious 
and benign training sets crossed each other. 
 
For machine learning based prediction of protein activity, two sets of input features 
were tested: One set consists of the score values returned by each of the 11 missense 
methods listed above. The other set consists of the binary assignments of benign or 
deleterious, represented as 0 or 1. Both feature sets also included the fraction of 
agreement (FOA) for a deleterious assignment across predictors, calculated as 
follows: 
𝐹𝑂𝐴 =  ∑ 𝐶𝑖
𝑖
  ∑ 𝑁𝑖
𝑖
⁄   
where the sum is over the number of missense methods included, and  𝑁𝑖 is 1 if a 
binary assignment is available for the i-th method, and is 0 otherwise, 𝐶𝑖 is 1 if the i-
th method predicted deleterious and is 0 if the i-th method predicted benign or was 
not available. 
 
Weka (Frank et al. 2016) with standard settings was used to test a number of machine 
learning models: logistic regression, linear regression, support vector machine (SVM) 
regression, multi-layer perceptron, M5 Rule, random tree and random forest. The 





supplementary methods), Pearson, and Spearman) on the PAH training set with 10-
fold cross validation was returned for an SVM regression with an RBF kernel with 
the default settings and using the 11 method scores and FOA as features. However, 
the spread of performance across the best combinations of the feature sets and the ML 
methods was small (Pearson’s r 0.84-0.87, RMSD 0.18-0.20, 10-fold cross validation) 
and so more extensive parameter optimization might have produced a different 
choice. In addition to the prediction of activity, CAGI4 rules also required estimated 
standard deviations for each activity value. I provided the RMSD on the PAH training 
set as the standard deviation for all predicted activities. 
 
2.3.4 Scale calibration and manual adjustment for each challenge 
The SVM regression model was used to predict the relative enzyme activity of each 
NAGLU mutation and the cell growth rate of each UBE2I (SUMO-ligase) mutation. 
Because the model was trained on a different gene (PAH) with enzyme activity 
measured using a different experimental assay, we expected some systematic bias in 
the predictions and assumed that results would require scaling for each challenge 
system. For NAGLU, a zero activity reference point was defined using 15 known 
disease mutations with reported zero enzyme activity (Beesley et al., 2004; Lee-Chen 
et al., 2002; Tessitore et al., 2000; Weber et al., 1999). A full activity reference point 
was defined by the 278 NAGLU interspecies variants compiled in the same way as the 
PAH interspecies variants described above. These reference points were used to 
linearly scale the NAGLU activity predictions. I also collected structural information 





(Guerois et al., 2002) predictions, as well as information on the functional role of 
individual residues from UniProt (UniProt Consortium, 2015). Two predictions 
affecting disulfide bonds were manually adjusted to 0.1 activity. Predictions for six 
residues were adjusted to lower predicted activity in an ad hoc manner, on the basis 
of predicted structure destabilization. The experimental data later showed that these 
manual adjustments did not improve overall prediction accuracy, and increased 
prediction error for three of the six residues. For SUMO-ligase, the distribution of 
experimental measurements was provided as part of the challenge. Two submissions 
were made using different calibration procedures. For the first, I used the closest 
experimental values to 0 and 1 as the zero and full growth rate reference points and 
applied a linear scaling procedure like that used for NAGLU. In the second 
submission, each predicted growth rate was uniquely matched to the corresponding 
ranked experimental value. We noted that the experimental distributions have a 
number of mutations with growth rates significantly higher than wild-type. For each 
challenge set, for the submission not mapped to the distribution of experimental data, 
it was necessary to reassign some growth rates to values greater than wild-type to 
match experiment. I increased the values for the top predicted growth rate subset, 
except for those that predicted destabilizing by SNPs3D Stability (Yue et al. 2005) 
and FOLDX (Guerois et al. 2002). I also took into account (Bernier-Villamor et al. 
2002; UniProt Consortium 2015) several reports of mutations with enhanced growth 
rate. The experimental data showed that this procedure is less accurate than that 
without manual adjustments on most gain-of-function mutations (22 of 27 in set 1 and 





sample, we assumed that the highest impact prediction dominated, and assigned that 
predicted value. The results of each challenge presented throughout the rest of the 
manuscript are based on a final set of predictions that include the manual adjustments. 
 
All final predictions were adjusted to be 0 if below 0, as required by the CAGI4 
submission instructions. 
 
2.3.5 Positive and negative controls 
Positive and negative control models were used to further evaluate the continuous 
predictions of relative protein activity. The positive control model estimated the 
performance expected if the computational method were perfect so that the only 
discrepancies arose from experimental error. For this purpose, simulated experimental 
errors were randomly drawn from a Gaussian distribution using the reported 
experimental mean and standard deviation based on the experimental error for each 
mutation. The performance was averaged from 1000 repeats of this process. The 
negative control adopted the algorithm proposed by the CAGI SUMO-ligase assessor 
as follows: 
Prediction Score = ln (
𝑃𝑚
𝑄𝑚




Where 𝑃𝑤 and 𝑃𝑚 are the probability of the wild type and mutated residue type 
occurring at the mutated position in a multiple sequence alignment and 𝑄𝑤 and 𝑄𝑚 
are the background frequencies of the wild type and mutated residue respectively in 





2.3.6 Analysis of the influence of training set type and size on performance 
The continuous value prediction models used a small training set of mutations and 
that set was from an unrelated protein. Once the submissions were made and the 
experimental data were available, for each of the challenges, I tested the influence of 
these factors as follows. 15% of the data was set aside for testing and a series of 
subsets of different sizes were randomly selected from the remainder. The machine 
learning model was retrained on each of these subsets. The procedure was repeated 10 
times, omitting a different 15% data each time. Performance was then evaluated as a 
function of training set size. 
 
2.3.7 Training and testing data for the binary predictor 
For training ensemble binary predictors of pathogenicity, all mutations in an earlier 
version of HGMD (Stenson et al., 2003) were used as true positives and a set of 
interspecies variants were used as true negatives (‘benign’ mutations), compiled by 
comparing homolog protein sequences across species with at least 90% sequence 
identity over at least 80% of the full length (Yue & Moult, 2006). For testing 
pathogenicity models and assessing prediction reliability, I compiled two independent 
test data sets. The first set is composed of ClinVar (Landrum et al., 2016) variants 
with pathogenic or benign assignments, excluding all that are in HGMD (2014 
version) (Stenson et al., 2014) and OMIM (http://omim.org/) in order to ensure 
independence from the commonly used training data. ClinVar ‘likely pathogenic’, 
‘likely benign’ entries, and entries with conflicting ClinVar assignments were not 





mutations. A complication in this analysis is choosing an activity level below which 
all mutations are pathogenic (that is, penetrance is 100%).  In other data referenced by 
the data provider, pathogenic mutations are found at activities up to 45% but most are 
below 15%. Because of this uncertainty, I evaluated methods performance using both 
10% and 30% relative enzyme activity cutoffs for pathogenicity. 
 
2.3.8 Pathogenicity prediction models 
Three machine learning methods were tested for binary state (pathogenic/benign) 
prediction models: Logistic Regression (Weka), Random Forest (Weka) and SVM 
(RBF kernel, SVMlight (Joachims 1999)). Features sets were the same as those used 
for continuous value prediction except that Panther and SNAP2 predictions were 
removed due to the difficulty of collecting the large number of predictions required 
from the corresponding web-servers. Models were trained using the HGMD dataset 
with default parameters. REVEL (Ioannidis et al., 2016) predictions were 
downloaded from (https://sites.google.com/site/revelgenomics/). The dbNSFP2.9 
database (X. Liu et al., 2013) was used to map REVEL results to individual protein 
mutations. 
 
2.3.9 Measuring prediction reliability 
In the clinic, variants are often accepted as pathogenic or benign if the 
confidence in that assignment is estimated as greater than some threshold, typically 





variants that were predicted with reliability (PPV, positive predictive value, see 
supplementary methods) at 95%, 90%, 85% and so on. To this end, for each method, 
the data were sorted by the associated prediction score, from highest confidence score 
to lowest. For prediction of pathogenicity, the fraction of highest confidence variants 
with a given PPV was then determined. The resulting fractions versus PPV curves 
were plotted using R ggplot2 (Wickham H, 2009)(Wickham 2009). To reduce noise, 
the NAGLU dataset was expanded to 1000 variants by bootstrapping, and assessed by 
averaging over 1000 bootstrappings. 
 
2.3.10 Measures of performance 
For predicted NAGLU enzyme activity and SUMO-ligase yeast growth rate, I 
calculated the root mean square deviation (RMSD) as follows:   






𝑖  and 𝑋𝑒𝑥𝑝
𝑖  are the predicted and experimental value of the i-th mutation. I 
used in-house programs and EXCEL2013 to calculate the Pearson’s r and the 
Spearman’s rho. The true positive rate and false positive were defined as following: 








The area under the receiver operating characteristic (ROC) curves (AUC) were 
approximated using the R package pROC (Robin et al., 2011). AUCs of different 





1988). When testing on the HGMD training set, I performed 10-fold cross validation. 
For evaluation of the accuracy of probability of pathogenicity estimates, the positive 
predicted value (PPV) is defined as follows: 






2.4.1 Comparison of predicted and experimental enzyme activities 
Figure 2-1A shows a scatter-plot for the NAGLU challenge mutations showing the 
relationship between all predicted and experimental enzyme activities. The overall 
RMSD between predicted and experimental values is 0.31, Pearson’s r is 0.55, and 
Spearman’s rho is 0.57. These values are worse than the cross validation results on 
the PAH training data, which are RMSD of 0.20, Pearson’s r of 0.82 and Spearman’s 
rho of 0.78. The NAGLU predicted values are also substantially worse than the 
positive control ‘perfect prediction’ RMSD of 0.12, 0.95 Pearson’s r and 0.94 
Spearman’s rho (based on the reported experimental standard errors). There are a 
small number of serious outliers, and as the plot shows, most of these correspond to 
mutations identified by the assessor as ‘hard to predict’ on the basis of poor 
performance by all the top methods. A breakdown of performance by location in the 
structure (Figure 2-2) shows striking variations for the Pearson’s correlation 
coefficient of 0.83, 0.50 and 0.39 for buried, partially exposed and surface mutations 
respectively. (Variant location based on the STRIDE (Eisenhaber & Argos, 1993; 





relative surface accessibility: buried core (≤ 0.05), partially exposed (> 0.05, ≤ 0.25) 
and surface (> 0.25)). The most serious outliers for both under and over-prediction of 
activity are in the partially or completely exposed subsets. Performance metrics are 
substantially improved omitting these ten, with RMSD of 0.24, Pearson’s r of 0.71 

















Figure 2-1. Prediction results for NAGLU and UBE2I (SUMO-ligase) mutations. 
Figure 2-1A. Scatter-plot comparing experimental NAGLU relative enzyme 
activities (Y-axis) with the predicted values (X-axis) for the CAGI challenge variant 
set. Dashed lines delineate the expected prediction RMSD from based on training 
results. 61% of the predicted values are within the range of the estimated RMSD, but 
a few mutations have very large deviations from the experimental measurements. The 
over-estimates shown in orange and the under-estimates shown in green are the ten 
mutations selected by the assessor as ‘hardest’ to predict. See text and Figure 2-2 and 
2-3 for a discussion of these. 
Figure 2-1B. Scatter-plot comparing experimental relative yeast growth rates with 
the mapped predicted values for the SUMO-ligase CAGI challenge UBE2I mutation 
Set 1. Dashed lines delineate the expected prediction RMSD from the training on 
phenylalanine hydroxylase mutations. The correlation with experiment is 
substantially weaker than for the NAGLU challenge (Figure 2-1A). 39% of the 






Figure 2-2. Scatterplot comparing experimental CAGI NAGLU relative enzyme 
activities with predicted values for three categories of surface accessibility. 2-2A) 
core residues, 2-2B) partially buried residues, 2-2C) exposed residues on the surface. 
Dashed lines delineate the expected prediction RMSD expected from training 
performance. Predictions are most accurate in the core and least accurate on the 
surface. Orange and green colored points represent mutations considered ‘hard’ by 









Table 2-1. Metrics of prediction performance for NAGLU and SUMO-ligase  
 
a In the SUMO-ligase challenge, we submitted two prediction sets, submission 1 using 
the scaled prediction scores (No Map), submission 2 (Mapped) mapping each 
predicted value to the experimental value of closest rank. 
b In the positive control, I estimate the expected difference between experiment and 
prediction, given the reported experimental errors. That is, a perfect prediction 
method could not be more accurate than this. See MATERIALS AND METHODS. 
c In the negative control, a prediction score was computed for each mutation based on 
amino acid frequency information only, using the equation described in 
MATERIALS AND METHODS. The resulting prediction scores were mapped to the 










Are the ten outlier mutations cases where all the prediction methods systematically 
fail, or are these experimental artifacts of some sort? A definitive answer to this 
question is not possible without further experiments, but in some cases, likely 
explanations present themselves. For example, 10 out of 11 individual methods in the 
ensemble model and a structural method, SNPs3D Stability, predict mutation 
(NAGLU NP_000254.2:p.A627V) to be benign, but the reported experimental activity 
value is close to 0. Consistent with the prediction results, examination of a multiple 
sequence alignment shows A627 is at a variable position across species, where 15 
different amino acid types are found. A627 is on the protein surface (Figure 2-3A) 
and the variant introduces a hydrophobic side chain (crystal structure from USPTO 
US08775146B2 (US08775146B2, 2014)). Under in vivo conditions, that may indeed 
have little impact, but in overexpression conditions of the experimental in vitro assay, 
aggregation may result. On the other hand, it is difficult to find any plausible 
explanation for some of the outliers. For example, one outlier (NAGLU 
NP_000254.2:p.P283L) is a partially exposed proline at an extremely conserved 
position (Figure 2-3B). All 11 individual prediction methods as well two structure-
based methods, FOLDX (Guerois et al., 2002; Schymkowitz, Borg, et al., 2005) and 
SNPs3D Stability (Yue et al., 2005), predict this mutation deleterious. Inspection of 
the structure suggests no way in which the leucine side chain could be 
accommodated. The reported experimental activity is the highest of any of the 








Figure 2-3. Structural view of two of the 10 ‘hard’ NAGLU outliers. Crystal 
structure is from USPTO US08775146B2. Mutated residues are yellow. Wild-type 
residues and environments in green, with a neighboring subunit in cyan. An N-
Acetylglucosamine molecule is in magenta, ordered water molecules are red crosses.  
2-3A 10 out 11 individual prediction methods and one structural method (SNPs3D 
Stability) predict A627V as benign, and it is a species variable surface residue, but 
reported experimental enzyme activity is only 0.08.  
2-3B All 11 individual methods and two structural methods, FOLDX and SNPs3D 
Stability, predict P283L as deleterious and the proline is highly species conserved, but 







Figure 2-1B is a scatter plot of the relationship between Submission 2 predicted and 
experimental growth rates for Set 1 UBE2I (SUMO-ligase) mutations. The 
performance is weaker (RMSD 0.55, Pearson’s r 0.39, Spearman’s rho 0.46) than the 
results for NAGLU, likely because of the complex relationship between aspects of 
SUMO-ligase function, its many substrates, and cell growth as well as effects from 
use of human protein in a yeast system. In contrast to NAGLU, the best performance 
is for surface residues (Pearson’s r 0.59), and it is less good for mutations of buried 
(Pearson’s r 0.35) and partially buried (0.29) residues. The results are worst for 
mutations in the substrate, SUMO, and SUMO-E3 ligase protein-protein interfaces 
((Pearson’s r 0.24, Figure 2-4). For example, in the experimental structure with a 
human SUMOylation substrate, RANGAP1 (PDB code 3UIP), the wild-type K74 
forms a salt bridge with E526 of the substrate (Figure 2-5). Mutations (UBE2I 
NP_003336.1:p.K74S and UBE2I NP_003336.1:p.K74E) disrupt that interaction and 
in the case of K74E electrostatic repulsion is introduced. Both positions are 
conserved, and the mutations are overwhelmingly predicted deleterious, yet the 
experimental growth rates are higher than wild-type. On the other hand, mutation 
(UBE2I NP_003336.1:p.K74R) appears to enhance the salt bridge with E526, and 
four out of ten sequence methods and the two structure methods predict it as benign. 
Yet the experimental value shows complete loss of growth. At the CAGI meeting the 
data provider, Fritz Roth, agreed that a possible complication here is that interfaces 
between human SUMO-ligase and its human partners may have significantly different 
properties from the equivalent yeast interfaces, and that in general the substantial 






Figure 2-4. Scatterplots of the experimental SUMO-ligase set 1(Y-axis) relative cell 
growth rate versus predicted values. Mutations are divided into four categories based 
on solvent accessibility: 2-4A) surface residues, 2-4B) core residues, 2-4C) partially 
exposed residues and 2-4D) residues at the interfaces to SUMO, SUMO E1 ligase and 
SUMO E3 ligase. The dashed lines delineate the expected RMSD from the training 
on phenylalanine mutations. The best performance is for surface residues, and the 







Figure 2-5. Structural view of three SUMO-ligase mutations of the same residue 
where predictions have large errors (PDB code 3UIP). Under-predicted mutation 
outliers (K74S and K74E) are orange and an over-predicted mutation outlier (K74R) 
is magenta. Wild-type residue K74 and its environment are green, and a SUMO-
ligase substrate (RANGAP1) is cyan. K74R should make a stronger salt bridge to 
E526 than the wild-type K74 and consistent with that four individual sequence 
methods and two structure methods, SNPs3D Stability and FOLDX, predict this 
mutation as benign. The experimental value shows zero growth rate. On the other 
hand, most of the individual methods and FOLDX predict K74S and K74E 
deleterious and the structure shows these two mutations likely disrupt the contacts 
with the substrate residue. K74E may also induce electronic repulsion. But the 
experimental growth rates are higher than wild-type. Discrepancies for these and 
other interface-related mutations may reflect differences between human and yeast 





Table 2-2. Total number of variants in each dataset, and coverage of these by 
different prediction methods, for each dataset used. The SUMO-ligase set includes all 
non-redundant single mutations in CAGI challenge set 1, set 2 and set 3. ClinVar 
consists of ‘pathogenic’ and ‘benign’ missense variants excluding those also found in 





Some other SUMO-ligase substrates do not have exactly the same interface (Bernier-
Villamor, Sampson, Matunis, & Lima, 2002). Thus, in general, it is not clear how 
altering the interface with one substrate may affect interactions with other substrates, 
and therefore what the overall effect on growth may be. 
 
Table 2-1 summarizes all the agreement statistics between prediction and experiment 
for the NAGLU mutations and the UBE2I (SUMO-ligase) set 1, set 2 and set 3 
mutations, together with the values for the positive and negative controls. (Data are 
for the SVM regression models described in Materials and Methods). Table 2-2 
shows the number of missense analysis methods reporting for each data set. The 
results show our models outperformed the (quite sophisticated) negative control in the 
NAGLU challenge (RMSD 0.31 versus 0.42, Pearson’s r 0.55 versus 0.45, and 
Spearman’s rho 0.57 versus 0.48). The model is also effective on the SUMO-ligase 
set 1 (the most reliable single mutations) when compared to the negative control 
(RMSD 0.55 versus 0.59, Pearson’s r 0.39 versus 0.30, and Spearman’s rho 0.46 
versus 0.38). The large gap between the method’s performance and the positive 
control suggests that experimental error was likely not the limiting factor in the level 
of agreement with experiment. 
 
2.4.2 NAGLU and SUMO-ligase challenge variant properties 
The NAGLU challenge data are extracted from the ExAC database of population 
variants (Lek et al., 2016). In this respect it is a unique dataset – a set of variants 





related mutations in databases such as HGMD (Stenson et al., 2003) and Clinvar 
(Landrum et al., 2016) and control sets of variants such as interspecies differences 
that are typically used for training and benchmarking methods. It is therefore of 
interest to ask how different the overall properties of these population variants are 
from the variants in the standard databases. Figure 2-6A shows that the predicted 
relative enzyme activity for the 90 NAGLU disease variants in HGMD and for 278 
NAGLU interspecies variants have distinct distributions centered on 0 and 0.9~1 
respectively, as expected. In contrast to this, the predictions for NAGLU CAGI 
challenge variants are approximately evenly distributed across the whole 0 to 1 range, 
in a manner similar to that of the experimental data. 
 
Figure 2-6. Distributions of predicted and experimental enzyme activities 
Figure 2-6A. Distribution of NAGLU relative enzyme activities 1) predicted for 
disease mutations in HGMD (HGMD, red); 2) predicted for inter-species variants 
(Interspecies, green); 3) predicted for mutations provided for the CAGI challenge 
(Prediction, blue), and 4) experimental activities for the challenge mutations 
(Experiment, purple). As expected, known disease mutations are predicted to have 
low activities and interspecies variant to have high activity. In contrast to these, the 
population variants have activities approximately equally distributed across the full 
range, for both prediction and experiment. 
Figure 2-6B. Relative yeast growth rate distributions for UBE2I (SUMO-ligase) 
mutation Set 1. The distribution of the unmapped predicted values (Submission 1, 





available during the challenge. We submitted a second set of predictions in which 
each predicted value was mapped to the experimental value of closest rank 
(Submission 2, blue). This improves the overall match of the distributions (red and 
black) but not the prediction accuracy. 
(Figure 2-6. See above for caption.) 
 
Figure 2-6B shows a comparison of the distribution of predicted yeast growth rates 
for SUMO-ligase challenge Set 1 mutations compared to the experimental 
distribution. An unusual feature of the experimental distribution is a substantial 
number (19%) of gain of function mutations, and this resulted in a poor overall fit 
from our prediction model. For submission 1, the distribution at low growth rates 
(below 0.2) is close to experiment, but between 0.2 and 1.0 there are too few 
predicted values and there are too many moderate gain of function values (in the 1.0 
to 1.4 range). The second submission, which mapped each predicted value to the 
closest experimental value, corrects these distribution errors and produced a better 
overall distribution but doesn’t improve the prediction accuracy (Table 2-1). Set 2 





presumably because of the presence of multiple mutations in each sample (Figure 2-
7). 
 
Figure 2-7. Distributions of experimental and predicted relative yeast growth rate 
distributions for the SUMO-ligase mutation Set 2 (A) and Set 3 (B). The distribution 
of the predicted values for our first submission (Submission 1, red) overestimates the 
number of experimental gain of function mutations (Experiment, black). The second 
submission (Submission 2, blue) corrects for this effect by mapping each value to the 
closest ranked experimental value. Set 3, with multiple mutations in each sample, has 
fewer gain-of-function mutants, as expected. 
 
2.4.3 Role of structure destabilization 
Thermodynamic destabilization of three-dimensional structure is established as 
playing a large role for monogenic disease-causing mutations (Yue et al., 2005), so it 





analysis was undertaken after the results were known, and did not form part of our 
CAGI submissions). Figure 2-8A shows the distribution of destabilization scores 
from SNPs3D (Yue et al., 2005) for the NAGLU homo-trimer complex. At a NAGLU 
pathogenicity activity threshold of 0.3, a high fraction (68%) of the low activity 
variants are destabilizing, so, as in other monogenic diseases, this factor plays a major 
role. 
 
The structure analysis is independent of the sequence methods and so provides some 
evidence for whether or not the 10 ‘hard’ predictions are experimental artifacts or 
systematic failures of the sequence methods. Two of the ‘hard’ variants with high 
experimental activity (NAGLU NP_000254.2:p.P283L and NAGLU 
NP_000254.2:p.G596C) are predicted destabilizing, consistent with the sequence 
analysis results and inconsistent with experiment. One of the ‘hard’ very low activity 
(0.06) variants ((NAGLU NP_000254.2:p.R377H), Figure 2-8B) is found to be 
destabilizing though, consistent with experiment and in disagreement with some 
sequence methods (5 out of 11). Wild-type R377 makes charge-dipole interactions 
with two main chain carbonyl groups (T343, A345) and a side chain hydroxyl group 
(Y335) so stabilizing a turn, and these interactions are absent for the variant (Figure 
2-8B). The other seven ‘hard’ variants are all low activity and predicted to be not-
destabilizing (lower right quadrant in Figure 2-8A). This could be because some other 
mechanism (for example involvement in catalysis) causes the low activity or because 
of experimental artifacts. Inspection of the structural environment does not reveal any 





17% of the stability predictions disagree with the experimental data – predicted 
destabilizing but with higher than pathogenic activity. These partly reflect the 
shortcomings of present stability analysis methods as illustrated by the example of 
mutation (NAGLU NP_000254.2:p.D306G) (Figure 2-8C). Wild-type D306 forms 
electrostatic interactions with R234 that is absent for the variant. In reality, loss of 
this interaction is likely largely compensated for by increased solvation energy, a 
factor poorly represented in the SNPs3D model. There is scope for improvement of 
these methods in this and a number of other ways.  
 
Figure 2-8. The role of thermodynamic destabilization in loss of function mutations.  
2-8A) Scatter plot comparing SNPs3D stability scores with experimental relative 
enzyme activity of NAGLU. Blue point variants in the lower left quadrant (68% of all 
those with low (< 0.3) activity) are predicted to destabilize the structure. Those at the 
upper right are predicted not destabilizing, consistent with their high activity. Those 
at the lower right (gray) are predicted to have low activity for reasons other than 
destabilization. The upper left quadrant variants (orange) are predicted destabilizing 
even though the experimental activity is high. Triangles show the location of the ten 
‘hard to predict’ variants. 
2-8B) Structural context of NAGLU ‘hard’ outlier R377H (red in [A]). Predicted 
destabilization is consistent with the low experimental activity. A substantial fraction 





2-8C) Structural view of variant D306G (red in [A]), predicted to be destabilizing, 
inconsistent with the experimental activity. Although the variant disrupts some 
electrostatic interactions, these are likely compensated by greater solvation. (Cyan: 
wild-type residues and interaction partners, orange: variants). 
 





2.4.4 Effect of training set size and choice of training data 
One obvious drawback to my approach is the limited number (activities for 231 
phenylalanine hydroxylase mutations) of training data. Further, training on that single 
system may introduce systematic bias. In order to evaluate whether the performance 
of the model is restricted by these two factors, I retrained using the NAGLU enzyme 
activity data, after these were released to the CAGI community (see Materials and 
Methods). A range of training set sizes was used to determine the contribution of that 
factor to accuracy. For each size, I retrained and measured performance, and averaged 
over 10 repeats. For each training, 15% of the data were randomly chosen for 
evaluation, and omitted from training.  Figure 2-9 shows that performance converged 
rapidly as the size of the training set increased beyond 100 mutations, showing that 
training set used in the CAGI challenges was large enough and not a factor limiting 
accuracy. Comparison between the converged performance and the performance in 
the blind CAGI challenges showed only a slight improvement of 0.05 RMSD and 
0.07 Spearman’s rho for NAGLU and 0.08 RMSD for SUMO-ligase, so that the loss 
of performance from training on the phenylalanine hydroxylase system is small. 
Similar results were obtained for the SUMO-ligase challenge. Together, this analysis 
shows that the results were not substantially limited by either the training set size or 
training on a different system, and other factors must account for the worse than 






Figure 2-9. Blue: average training set performance, green: average test set 
performance (15% of data omitted from training). Averages over 10 runs. Purple 
rectangles show performance in the CAGI challenge with the model trained on PAH. 
2-9A) RMSD, 2-9B) Spearman rank correlation coefficient. Prediction performance 
converges rapidly as the training set size increases beyond 100 mutations. Training on 
the target protein rather than Phenylalanine hydroxylase (PAH) only slightly 
improves performance (0.05 RMSD and 0.07 Spearman’s rho). Thus, training set size 
and training on PAH are not limiting factors in performance. 
 
2.4.5 Predicting pathogenicity using ensemble methods 
Post-challenge, I also investigated how well ensemble methods perform on assigning 
pathogenicity in the clinically relevant NAGLU data, compared with performance on 
standard benchmarking datasets.  For these binary predictions (pathogenic/not 





(Kircher et al., 2014), LRT (Chun & Fay, 2009), MutationTaster (Schwarz et al., 
2010), PON-P2 (Niroula et al., 2015), PPH2 (Adzhubei et al., 2010), PROVEAN 
(Choi et al., 2012), SIFT (Ng & Henikoff, 2003), SNPs3D Profile (Yue & Moult, 
2006) and VEST3 (Carter et al., 2013)) with three machine learning models (Logistic 
Regression, Random Forest, and SVM). Training was performed on a version of 
HGMD (Stenson et al., 2003) and a set of interspecies variants (see Materials and 
Methods). Results were evaluated using 10-fold cross-validation. When tested on 
HGMD, the ROC curves and AUCs of the ensemble machine learning predictors 
show better performance than any of the individual methods, with the highest AUC of 
0.98 (Figure 2-10A and Table 2-3), although most perform extremely well. A number 
of individual predictors are partially or completely trained on HGMD, so to control 
for this factor, I also tested on a subset of ClinVar variants not in HGMD or OMIM 
(another common source of training data). (Figure 2-10B and Table 2-3). Though still 
better than most individual predictors, my ensemble predictors (best AUC 0.95) were 
slightly but significantly outperformed by VEST3 (Carter et al., 2013) (AUC 0.96) 
and the new ensemble method REVEL (Ioannidis et al., 2016) (AUC 0.97). As 
Figures 2-10C and Table 2-3 show, when the same methods were tested on the more 
relevant challenge NAGLU variant set, all showed substantially deteriorated 
performance (AUC up to 0.84 for the ensemble methods, slightly better than any 
other tested methods). Relative performance is insensitive to the exact activity 
threshold for pathogenic loss of activity (Table 2-3). I also converted the continuous 
NAGLU activity predictions to binary assignments and generated a ROC curve. That 





distribution of activities found in the general population (all activities approximately 
equally likely to be encountered) are much more challenging for all methods than 
distinguishing between only pathogenic and interspecies variants.   
 
Figure 2-10. ROC (receiver operating characteristic) curves for predictions of 
pathogenicity by the new ensemble methods and other methods on HGMD, ClinVar 
unique and NAGLU challenge sets. For NAGLU, the pathogenicity threshold is an 
activity of 0.3 of wild-type. The AUC (area under curve) of these ROC curves are 
listed in Table 2-3.  
2-10A For HGMD test data, the new ensemble models (Logistic Regression 0.98, 
Random Forest 0.98 and SVM 0.97) outperformed all constituent individual 
predictors on the HGMD test dataset. PPH2 and VEST3, which were also trained 
partially or completely on HGMD, have slight but significantly (P-value < 2.2e-6) 
worse AUCs.  
2-10B For the unique ClinVar dataset (no overlap with HGMD or OMIM), another 
ensemble method, REVEL, outperformed all other methods. The next highest AUCs, 
for VEST3 and my ensemble models, are slightly but significantly (P-value < 0.05) 
smaller.  
2-10C For the NAGLU rare population variants, all methods perform substantially 
worse than on HGMD and ClinVar. My ensemble FOA (fraction of agreement) 





Forest models, and VEST3. All four are not significantly different from each other 
(P-values > 0.05). 
 
















a Ensemble model combining nine individual missense mutation analysis methods 
b Fraction of the nine methods making a deleterious assignment 
c Using NAGLU relative activity cutoff of 0.1 





2.4.6 Reliability of pathogenic assignments 
I investigated the effectiveness of ensemble methods for estimating the reliability of 
pathogenic assignments using the results from the binary pathogenicity analysis 
described above. To examine whether there is a useful ensemble signal to be 
exploited, I first examined the PPV as a function of the fraction of methods agreeing 
on a deleterious assignment (FOA) for the HGMD and interspecies dataset. Table 2-2 
shows the number of methods included. There is strong dependence of PPV on FOA 
with the HGMD set (Figure 2-11A): For the set of variants where all nine methods 
predict deleterious, the PPV is 0.97 and the PPV is above 0.9 even when only 7 out of 
9 methods predict deleterious. At the other end of the scale, the PPV is 0.04 when no 
method predicts deleterious and still below 0.1 even where two methods predict 
deleterious, so that in all 78% of mutations have better than 90% confidence 
assignments of either pathogenic or benign (Figure 2-11B). Thus even a very simple 
ensemble method shows promise for this purpose.  
 
Figure 2-11 Initial results of estimating assignment reliability 
2-11A. Relationship between the fraction of methods that agree on a deleterious 
assignment (FOA) and the positive predictive value, PPV (fraction of predicted 
pathogenic variants that are pathogenic), for HGMD and interspecies variants.  
2-11B. Fraction of variants in each bin. Approximately 39% of variants can be 
predicted pathogenic with 90% or greater confidence (PPV) and 39% can be 





demonstrated a potential usefulness of ensemble methods in assigning prediction 
reliability. 
(Figure 2-11. See above for caption.) 
 
A fuller analysis is shown in Figure 2-12. Here the fraction of variants meeting a 
given reliability threshold is plotted as a function of the threshold, for both confidence 
in pathogenicity (top panels) and non-pathogenicity (bottom panels). As with the 
pathogenicity assignment results above, my ensemble methods and REVEL perform 
best on the HGMD and ClinVar sets respectively. Also as with the pathogenicity 
assignment, performance is substantially better on the HGMD and ClinVar test sets 
than on the NAGLU data. For HGMD, the best methods assign pathogenicity with 
90% or greater confidence for 90% of the data, and benign assignments with equal 
confidence are made for about 75% of data. Pathogenicity confidence on the ClinVar 
set is similar, with a higher fraction meeting 90% confidence criterion (96%) for 
benign assignments. For the more realistic NAGLU dataset using an activity of 0.3 as 





better accuracy, and 56% benign assignments are 90% or better correct. However, the 
dependence of accuracy on the threshold is steep for both these numbers, and precise 
values are likely to be dataset specific. Overall, the results do show that ensemble 
methods are advantageous for assigning reliability to pathogenicity assignments, and 
that the fraction of variants for which 90% confidence can be reached in the clinic is 
likely quite high. More realistic datasets such as the NAGLU one are needed to 
further investigate these properties.  
 
Figure 2-12. Fraction of data for which pathogenicity or benign status is predicted at 
a specified level of confidence, as a function of the confidence level, for HGMD (2-
12A, 2-12B), ClinVar (2-12C, 2-12D) and the NAGLU challenge dataset 
(pathogenicity cutoff of 0.3, 2-12E, 2-12F). Vertical dashed lines show the 0.9 
reliability threshold. For each dataset, the top panel shows the fraction of pathogenic 
variants meeting a reliability (PPV) threshold as a function of threshold and the 
bottom panel shows the equivalent data for reliability of benign assignment (NPV). 
My ensemble methods and REVEL perform best on the HGMD and ClinVar sets 
respectively. Overall, even in the demanding NAGLU dataset, a substantial fraction 









(Figure 2-12. See above for caption.) 
 
2.5 Discussion 
2.5.1 Ensemble methods for the NAGLU and SUMO-ligase challenges 
 The NAGLU and SUMO-ligase challenges are unusual in that CAGI participants 
were asked to predict a continuous variable – in the case of NAGLU, relative enzyme 
activity, and in the case of SUMO-ligase, relative growth rate in a yeast 
complementation assay. Most missense analysis methods are designed to make a 
binary assignment of pathogenic or non-pathogenic, and so are not immediately 





strategy, incorporating up to 11 of the binary assignment methods. Ensemble methods 
have already been shown to be effective for the binary pathogenicity assignment task 
(Capriotti et al., 2013; González-Pérez & López-Bigas, 2011; Ioannidis et al., 2016; 
Olatubosun et al., 2012). Here we assume that the more single methods make a 
pathogenic assignment for a given variant, the lower the corresponding protein 
activity will be. As the simple FOA (fraction of agreement between methods) 
approach demonstrates, this is the case. Use of confidence scores for each 
contributing method rather than binary values makes the procedure more nuanced, 
and machine learning provides a means of combining the methods in a balanced way. 
A potential limitation was the lack of suitable enzyme activity training data, but post-
challenge analysis showed that as few as 100 phenylalanine hydroxylase variant 
activities were sufficient, and also that there was no significant bias from training on 
that system. The ensemble approach was successful in that it performed well, 
although it was slightly behind the best performers. In the NAGLU challenge, the 
ensemble approach was marginally outperformed by MutPred2 (unpublished, -0.005 
in RMSD, +0.05 in Pearson’s r, +0.04 in Spearman’s rho and +0.00 in AUC) and by 
Evolution Action (Katsonis and Lichtarge 2014, -0.028 in RMSD, +0.001 in 
Pearson’s r, -0.019 in Spearman’s rho and +0.03 in AUC). In the SUMO ligase 
challenge, our two submissions of the ensemble approach performed best on set 1 and 
set 2 respectively, but were outperformed by most other methods on set 3 (multiple 
mutation set), probably due to the assumption that growth would be determined by 
the most deleterious mutation for each sample, rather than affected additively. For 





residue types are identical in human and yeast with that at positions where the 
residues are different. The former subset contains a relatively larger proportion of 
mutations with low relative growth rates. For example, there are more than twice as 
many zero growth mutations where the wild-type human and yeast residues are 
identical as opposed to different. But the performance of the ensemble method was 
not sensitive to this data partition (difference in RMSD ~0.07, in Pearson’s r ~0.06, 
and in Spearman’s rho <0.005). There is little difference between the fractions of 
wild-type identical residues versus non-identical for the subset of mutations with 
relative growth rates greater than 1.0. Neither our ensemble approach nor other best 
performers provided revolutionary accuracy. As discussed below, limitations in all 
contemporary approaches probably ensure that is not possible. 
 
2.5.2 Accuracy 
Although the methods used here and others in CAGI produce very strong statistical 
significance in terms of the relationship between predicted and experimental activity 
values, the agreement appears substantially less than expected, given the reported 
experimental accuracy.  What limits the accuracy? – Some part of the disagreement 
may be due to experimental artifacts. For example as noted earlier, for one of the 10 
NAGLU ‘hard’ variants the conditions of expression in the cell line may contribute to 
aggregation not encountered in vivo. For SUMO-ligase, as discussed in Results, 






Overall though, most of the discrepancy likely comes from the inherent deficiencies 
of the methods.  Nearly all primarily attempt to relate sequence conservation patterns 
to pathogenicity (some also incorporate partial structure information (Adzhubei et al., 
2010; Carter et al., 2013; Hecht et al., 2015)). Although there clearly is a qualitative 
relationship of this type, there is no theoretical framework providing a quantitative 
relationship. Such a framework would need to relate phylogenic profiles to fitness, 
something which the molecular evolution community has not succeeded in doing 
after many years of effort (Orr, 2009). Further, the relationship between fitness and 
disease relevance is also not straightforward. As a consequence, all current 
pathogenicity prediction methods are ad hoc, using calibration or machine learning to 
achieve some level of quantitation. Given that, they are surprisingly effective. There 
are a number of ways in which accuracy may improve in the future. In my results, 
there is markedly different accuracy for surface and interior residues, so that treating 
these classes of residues differently may be useful. Other structural and functional 
information may also help. Specific training only on variants where individual 
methods do not correlate well might be helpful, if there are sufficient data and an 
appropriate algorithm for training. More generally, at present, most methods are 
completely non-specific, and are applied to different proteins without incorporating 
information pertinent to each case. In future, we envision that protein specific models 
will be built. There is also a major requirement for more realistic training and testing 






2.5.3 Assigning pathogenicity 
As noted earlier, the NAGLU challenge data set is so far unique in that it consists of 
protein activity data drawn from a background population representative of that 
expected in the clinic. The commonly used HGMD and ClinVar databases, although 
useful compilations of clinically relevant data, are usually paired with highly benign 
controls for training and testing purposes, and so not very representative of clinical 
encounters. Therefore, I also tested an ensemble approach for assigning pathogenicity 
in the NAGLU dataset, compared to standard benchmarks. The new ensemble method 
and many others tested here perform extremely well on two standard benchmark sets, 
HGMD (Stenson et al., 2014) and a unique subset of ClinVar (Landrum et al., 2016), 
many with AUCs of over 95%. Both my ensemble method and another recent 
ensemble approach, REVEL (Ioannidis et al., 2016) have relatively good performance 
on the NAGLU data, but overall, all methods are strikingly less effective (best AUCs 
up to 0.84). The results suggest that we need many more clinically relevant datasets 
like NAGLU in order to realistically evaluate the pathogenicity assignment methods. 
 
2.5.4 Utilization of protein structure information 
As demonstrated here and in other work (Adzhubei et al., 2010; Baugh et al., 2016; 
Carter et al., 2013; Folkman et al., 2016; Hecht et al., 2015; Redler et al., 2016; Yue 
et al., 2005), analysis based on protein structure provides an orthogonal approach that, 
in spite of its own accuracy limitations, can sometimes provide valuable insight into 
the atomic level mechanisms in play. In particular, as with other monogenic disease-





fraction operate by destabilizing protein three-dimensional structure. There is 
considerable scope for further improvement of these approaches, using more 
biophysical approaches (Seeliger & de Groot, 2010). 
 
2.5.5 Reliability for pathogenicity assignments 
In the clinic a major concern is not just to have an accurate predictor of pathogenicity, 
but also to be able to have a reliable probability that an assignment of pathogenic or 
benign is correct: a method may be highly accurate some of the time and fail on a 
subset of variants, and it is important to know when the prediction can be trusted and 
with what confidence. Because of a lack of well-tested reliability estimates, present 
clinical guidelines allow computational methods of predicting pathogenicity only 
secondary status as evidence for establishing a genetic cause for disease symptoms 
(Richards et al., 2015). The challenge NAGLU data set provided an opportunity for 
testing methods of assigning such probabilities on a clinically relevant dataset.  The 
ensemble methods reported here, as well as other ensemble approaches such as 
REVEL (Ioannidis et al., 2016), are among the best for this purpose. Encouragingly, 
even on the realistic NAGLU population variants, a substantial fraction (up to 40%) of 
pathogenicity assignments can be made with greater than 90% confidence. More 
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Chapter 3: Characterizing and comparing missense variants in 




The large amount of genomic data now available for monogenic disease and for 
cancer has vastly expanded our knowledge of which mutations are involved in these 
diseases (Martincorena & Campbell, 2015; Shendure & Akey, 2015). In monogenic 
disease, over 7000 monogenic diseases and over 10,000 related genes have been 
described in the Online Mendelian Inheritance in Man (OMIM) database 
(http://omim.org/). In HGMD (Stenson et al., 2014), there are over 2,800 genes where 
some monogenic disease-causative mutations have been identified, over 50% of 
which are missense mutations. Sequencing of over 20,000 cancer sample exomes and 
a growing number of complete cancer genomes has revealed the mutation landscape 
for dozens of cancer types (Martincorena & Campbell, 2015; Vogelstein et al., 2013). 
Most of these data are available through three large consortia, the Cancer Genome 
Atlas (TCGA) (https://cancergenome.nih.gov/), the Catalogue of Somatic Mutations 
in Cancer (COSMIC, http://cancer.sanger.ac.uk/cosmic) and the International Cancer 
Genome Consortium (ICGC) (http://icgc.org). The mutation load found varies by 
more than two orders of magnitude among individual samples as well as by cancer 
type (Martincorena & Campbell, 2015; Vogelstein et al., 2013). For example, acute 
myeloid leukemia and some pediatric cancers may carry less than 10 nonsynonymous 





cancer and melanoma typically have an average of around two hundred (Alexandrov 
et al., 2013; Lawrence et al., 2014; Vogelstein et al., 2013). It has been generally 
accepted that only a small number of the somatic mutations (4-6 (Armitage & Doll, 
1954; Sabarinathan et al., 2017)) (the ‘drivers’) in each sample are responsible for the 
development of the disease. A recent comprehensive study estimates the average total 
number of driver mutations per sample as 4.6, including both SNVs and CNVs 
(Sabarinathan et al., 2017).  
 
A variety of mutation types may be causative of monogenic diseases or be cancer 
drivers, including single base changes resulting in effects on expression and splicing, 
amino acid substitutions (missense) and premature stop codons, as well as small 
insertions and deletions (Ciriello et al., 2013; Stenson et al., 2009), and particularly in 
cancer (Ciriello et al., 2013), copy number changes (large insertions or deletions, 
deleting or duplicating one or more genes).  Larger scale chromosomal changes also 
play a role in cancer, where genome instability is common (Stephens et al., 2011). In 
monogenic disease, and in contrast to complex trait disease (Gusev et al., 2014; 
Maurano et al., 2012; Nicolae et al., 2010), very few mutations affecting expression 
have been identified (Landrum et al., 2016). Data for non-coding contributions in 
cancer are only now becoming available. Some clear examples have been identified 
(Horn et al., 2013; Huang et al., 2013), but a clear picture has yet to emerge. In 
monogenic disease, the most common mutation type is missense (Stenson et al., 
2003), a single base change causing an amino acid substitution. In cancer, missense 





3.1.2 Missense mutations 
In this paper I use computational methods to analyze and compare the role of 
missense mutations in monogenic disease and cancer. There are three primary 
motivations. First, as noted above, this class of mutation is the most in common in 
both types of disease, so that a thorough understanding of its role is worthwhile. 
Second, unlike most indels and copy number variants which have a major impact on 
protein function and hence disease phenotype, missense mutations range from no 
effect on protein function to complete loss of activity. The wide range of possible 
molecular impact presents problems for clinical interpretation. As a result, at present, 
evidence from computational analysis is given low weight in clinical diagnosis in 
monogenic disease (Richards et al., 2015). Greater understanding of how these 
mutations influence disease phenotype will help improve the usefulness of the 
computational methods. Third, with many instances of these mutations now known in 
both types of disease, it is possible to perform statistical analyses that provide insight 
into the molecular mechanisms involved.   
 
3.1.3 Methods for interpretation of missense mutations 
Methods for imputing the disease relevance of missense mutations fall into two 
classes: Those that rely on the pattern of observed amino acid substitutions at a 
mutation position both across species and paralogs and as common variants within the 
human population, and those that make use of structural and other molecular function 
information. Sequence-based methods usually utilize machine learning, and typical 





position of interest  (Cooper & Shendure, 2011). An advantage of these methods is 
that, provided there is a deep enough, diverse enough, and stable alignment, any 
mutation can be analyzed (currently 92% of the reference set of monogenic disease 
mutations (Stenson et al., 2003) using SNPs3D profile (Yue & Moult, 2006)). 
Further, subject to the assumption below, they are effective for all types of underlying 
mechanisms including gain of function (highly relevant for mutations in oncogenes). 
The disadvantage is that they provide no insight into the mechanism by which a 
mutation is involved in disease. The methods implicitly assume that if a mutation 
plays a causative role in disease, it will affect Darwinian fitness, and thus tend to be 
selected against. Since many monogenic diseases are early onset and severe enough 
to affect reproductive success, that may be a reasonable assumption. Relevance to 
cancer, where driver mutations promote cell growth in many ways, is less obvious. 
Although the assumption of a relationship between an effect on fitness and disease 
phenotype is embedded in the methods, there is no formal theoretical framework for 
calculating fitness impact. Rather machine learning (Adzhubei et al., 2010; Carter et 
al., 2013; Douville et al., 2016; Kircher et al., 2014; Yue & Moult, 2006) or other 
parameterization (Lichtarge et al., 1996; Ng & Henikoff, 2003) is used to calibrate the 
relationship between amino acid substitution patterns and disease phenotypes in an ad 
hoc way.  
 
Protein structure and function provide a complementary, more mechanism oriented 
approach to identifying disease-relevant mutations. Previous studies have shown that 





mutations destabilize three dimensional-structure (Shi & Moult, 2011; Z. Wang & 
Moult, 2001; Yue et al., 2005): for a reference set of monogenic disease proteins 
(Stenson et al., 2003), SNPs3D_Stablity  (Yue et al., 2005) assigned 72% as 
destabilizing, and for the cancer set (Ciriello et al., 2013), 50%~60% (Shi & Moult, 
2011). Thus, methods of estimating the change in free energy difference between the 
folded and unfolded states introduced by an amino acid substitution play an important 
role. Molecular dynamics free energy perturbation methods (Seeliger & de Groot, 
2010) may be used for this purpose. Up to now, these methods have found limited 
application in studies of mutations because of relatively high computational cost and 
lower accuracy when compared with more empirical approaches. In this paper I use 
SNPs3D_Stability (Yue et al., 2005) to examine the role of destabilization in both 
monogenic disease and cancer.  The method uses empirical potential terms 
representing van der Waals interactions, electrostatics, conformational strain, solvent 
accessibility and local flexibility in a non-linear support vector machine model and 
was trained using monogenic disease data (Stenson et al., 2003) together with 
interspecies variants as controls. It has been benchmarked against experimental G 
data and monogenic disease mutations (Yue et al., 2005). The method returns a binary 
yes/no estimate of whether a missense variant destabilizes a structure sufficiently to 







3.1.4 Identifying driver mutations 
There are well-established databases of causative mutations for monogenic disease 
(Stenson et al., 2003), and although these sources are not error-free (Xue et al., 2012), 
they are sufficiently accurate for many statistical purposes. Reliable identification of 
cancer driver mutations remains a major problem, because of the high background of 
passenger mutations.  Current strategies focus on first identifying a subset of genes 
that contain driver mutations (‘driver genes’) and then determining which mutations 
in those genes are drivers. Driver genes are identified on the basis of containing a 
statistically higher number of cancer somatic mutations than sample background, 
together with other factors  (Davoli et al., 2013; Dees et al., 2012; Gonzalez-Perez & 
Lopez-Bigas, 2012; Leiserson et al., 2015; Mermel et al., 2011; Reimand & Bader, 
2013; Rubio-Perez et al., 2015; Tamborero, Gonzalez-Perez, Perez-Llamas, et al., 
2013; Tamborero, Gonzalez-Perez, & Lopez-Bigas, 2013; Vogelstein et al., 2013). 
Although a number of sets of driver genes have been proposed, there is limited 
agreement between them (Tokheim, Papadopoulos, Kinzler, Vogelstein, & Karchin, 
2016). It is very likely that some other genes contain some driver mutations, and 
conversely it is clear that driver genes will contain some level of non-driver 
(‘passenger’) mutations. In this work I used the driver gene sets derived from the two 
cancer mutation datasets I analyzed (Ciriello et al., 2013; Futreal et al., 2004).   
 
A number of methods for identifying individual driver missense mutations (Carter et 
al., 2009; Gonzalez-Perez et al., 2012; J. S. Kaminker et al., 2007; Mao et al., 2013; 





combinations driver gene lists, predicted impact of mutations, clustering of mutations, 
and the number of samples in which a mutation has been observed. A limited number 
of driver mutations have been reliably annotated, for example, a set of 889 (Catalog 
of Validated Oncogenic Mutations, 
https://www.cancergenomeinterpreter.org/mutations). Currently, these sets are too 
small for a statistical analysis of properties and because of the way they were derived 
(an emphasis on repeat occurrence for instance) likely have significant biases. I 
address the problem of uncertain driver mutation assignments by considering all 
mutations found in the sets of driver genes, and investigating properties of interest as 
a function of driver assignment confidence. 
 
3.1.5 Questions addressed 
We use the sets of monogenic disease and cancer driver mutations together with the 
computational methods to address the following questions: 
How effective are sequence-based methods for identifying mutations relevant to the 
two types of disease? As noted above, these methods depend on mutations impacting 
Darwinian fitness and, especially for cancer, the validity of that assumption is not 
clear. Technical issues may also limit accuracy. 
How important are intrinsically disordered regions of proteins compared with ordered 
regions in the two types of disease? The role of disordered regions in protein function 
has been much discussed (Midic, Oldfield, Dunker, Obradovic, & Uversky, 2009; 





What is the relative role of mutations on the protein surface versus those in the core 
of protein structures? Surface mutations are more likely to be involved in inter-
molecular interactions and other mechanisms, while core mutations will be enriched 
for effects on protein structure stability. 
How extensive is the role of destabilization of protein structure in the two types of 
disease? As noted above, this mechanism plays a major role in monogenic disease, 
but its role in cancer has been less clear. 
What are the properties of mutations in cancer passenger genes? Are these benign, as 
the ‘passenger’ designation implies?  
 
3.2 Methods 
3.2.1 Monogenic disease data and cancer data 
The monogenic disease set comprises 10,865 disease-related variants collected from 
an earlier version of HGMD (Stenson et al., 2003), together with 13,499 interspecies 
variants in these genes, compiled by comparing mammalian homolog protein 
sequences with at least 90% sequence identity over at least 80% of the full length and 
excluding any known disease-related variants (Yue & Moult, 2006). The disease 
genes can be classified as dominant or recessive based on their inheritance patterns. 
 
Two cancer driver data sets were compiled as follows. One set was extracted from the 
level 3 TCGA (Cancer Genome Atlas Network, Bainbridge, et al., 2012; Cancer 





Network et al., 2008, 2011, 2012; Cancer Genome Atlas Research Network, Getz, et 
al., 2013; Cancer Genome Atlas Research Network, Ley, et al., 2013) data described 
in (Ciriello et al., 2013), which has 449,788 unique somatic single-residue 
substitutions in a total of 3,477 tumor samples from studies on 12 different cancer 
types (Table 3-1). The TCGA driver set consists of the 9,325 unique somatic 
missense mutations found in 193 driver genes identified by (Ciriello et al., 2013). 
Another 415,090 somatic missense mutations in genes not belonging to the 193 driver 
gene list were extracted to form the TCGA passenger set. Mutations in other potential 
driver genes (Kumar, Searleman, Swamidass, Griffith, & Bose, 2015; Lawrence et al., 
2014; Martincorena & Campbell, 2015; Tokheim et al., 2016; Vogelstein et al., 2013) 
were also omitted in the passenger set. 27 oncogenes and 47 tumor suppressor genes 
were identified in the TCGA 193 driver gene list, based on the literature (Kumar et 
al., 2015; Tokheim et al., 2016; Vogelstein et al., 2013), providing a TCGA 
Oncogene set of 1,362 missense mutations and TCGA TSG set of 2,933 missense 
mutations. A set of 3,116 interspecies variants in the 193 TCGA driver genes were 
extracted using the same procedure as for the monogenic disease set described above.  
 
The second cancer data set was extracted from the 531,728 unique somatic single-
residue substitutions in the COSMIC Database (Forbes et al., 2017) version 68. The 
Cosmic Gene Census (CGC) driver dataset consists of the 30,773 missense mutations 
in 477 driver genes identified by the Cancer Gene Census (Futreal et al., 2004). 
Another 495,530 missense mutations extracted from the COSMIC non-CGC genes 





in the same way as for the TCGA passenger set. A CGC Oncogene set of 7,422 
missense mutations in 79 genes and a CGC TSG set of 12,016 missense mutations in 
81 genes were compiled using the same procedure as for the TCGA sets. A CGC 
interspecies variants set of 6448 missense mutations was extracted using the same 
procedures as above. 
 
Table 3-1. TCGA data set 
 
Tumor type TCGA ID 
Number of 
samples 
Number of unique 
mutationsa in 
driver genes 
    
Bladder urothelial 
carcinoma 
BLCA 100 17431 
Breast invasive 
carcinomab 
BRCA 513 17460 
Colon and rectum 
adenocarcinomac 
COADREAD 498 100020 
Glioblastoma 
multiformaed 
GBM 276 21531 
Head and neck 
squamous cell 
carcinoma 
HNSC 306 34079 
Kidney renal clear-
cell carcinoma 
KIRC 473 15557 
Acute myeloid 
leukemiae 
LAML 201 2500 
Lung adenocarcinoma LUAD 230 44092 
Lung squamous cell 
carcinomaf 
LUSC 177 44883 
Ovarian serous 
cystadenocarcinomag 




UCEC 247 106141 
    
 
aRestricted to somatic nonsynonymous single-residue substitutions observed in 
samples of each specific cancer types.  





cReference see (Cancer Genome Atlas Network, Bainbridge, et al., 2012) 
dReference see (Cancer Genome Atlas Research Network et al., 2008) 
eReference see (Cancer Genome Atlas Research Network, Ley, et al., 2013) 
fReference see (Cancer Genome Atlas Research Network et al., 2012) 
gReference see (Cancer Genome Atlas Research Network et al., 2011) 
hReference see (Cancer Genome Atlas Research Network, Getz, et al., 2013) 
 
3.2.2 Missense mutation analysis methods 
Seven sequence-based missense analysis methods were used to assign missense 
mutations as deleterious or benign and the fraction of those mutations that are 
assigned as deleterious (the PDF, predicted deleterious fraction) was then calculated. 
Four of these (SNPs3D Profile (Yue & Moult, 2006), PolyPhen-2 (Adzhubei et al., 
2010), CADD (Kircher et al., 2014), VEST3 (Carter et al., 2013; Douville et al., 
2016)) were trained on monogenic disease mutation datasets (except CADD which 
was trained differently). The rest three: SIFT (Ng & Henikoff, 2003), LRT (Chun & 
Fay, 2009), and PROVEAN (Choi et al., 2012) rely on direct measures of sequence 
conservation properties and do not require training. In addition, three sequence 
methods trained specifically for interpreting cancer mutations were tested: FATHMM 
(Shihab, Gough, Cooper, Day, & Gaunt, 2013), Mutation Assessor (Reva et al., 2011) 
and CHASM (Carter et al., 2009; Wong et al., 2011). SNPs3D Profile results were 
generated using standalone in-house software. The dbNSFP2.9 database (X. Liu et al., 
2013) was used to obtain PolyPhen-2, CADD, SIFT, LRT, VEST3, PROVEAN, 
FATHMM and Mutation Assessor results. CHASM results were obtained from the 
CRAVAT Web server (http://www.cravat.us/CRAVAT/). Binary assignments of 





Li, & Moult, 2005) with in-house software and the predicted destabilizing fractions 
(PDFs) were calculated from those data. 
 
Binary predictions were collected for PolyPhen-2, SIFT, LRT, PROVEAN, 
FATHMM and Mutation Assessor. The HumDiv version of PolyPhen-2 was used, 
and “probably damaging” and “possibly damaging” predictions were considered 
deleterious. MutationAssessor “H” and “M” predictions were also considered 
deleterious. Three methods (CADD, VEST3, and CHASM) reported continuous 
scores rather than binary assignments. Dataset-specific score thresholds were chosen 
for these, such that the false positive rates on the corresponding interspecies variants 
sets are similar to that of other methods. For the monogenic disease data, the score 
thresholds are 22 for CADD, 0.5545 for VEST3, and 0.095 for CHASM. On the 
TCGA data, the thresholds are 21.35 for CADD, 0.2815 for VEST3, and 0.1395 for 
CHASM. On the Cosmic data, the thresholds are 21.35 for CADD, 0.2915 for 
VEST3, and 0.1225 for CHASM. 
 
To assess potential training bias, SNPs3D Profile and SNPs3D Stability methods 
were retrained on the two cancer data sets and on specific subsets of monogenic 
disease data. In retraining, all parameters in the support vector machine (SVM) 
models were re-optimized with a grid search algorithm. At each search step, the 
corresponding data set was bootstrapped 30 times, with the model trained on a set of 





on the data points not included in training. 95% confidence intervals in the other 
analyses were also inferred from 30 rounds of bootstrapping.  
 
3.2.3 Structure modeling 
For analysis of structure-related features, the set of experimental protein structures 
was extended by building homology models for protein domains where a suitable 
template was available, as described in (Yue et al., 2005). The procedure is briefly 
summarized here. Proteins that have > 40% sequence identity to the query protein and 
a crystal structure of < 3Å resolution are used as templates for backbone 
conformations. The 40% sequence identity cutoff is based on earlier benchmarking 
(Yue et al., 2005) that showed prediction accuracy for models based on 40% or higher 
sequence identity to a template is not significantly lower than for that based on 
experimental structures. Where the template amino acids are identical to the 
corresponding ones in the query structure, side chains atoms from the template are 
used. Otherwise, the side-chains are modeled using SCWRL (Canutescu, Shelenkov, 
& Dunbrack, 2003). 
 
3.2.4 Analysis of somatic missense mutation recurrence and density 
For each unique cancer somatic missense mutation, the recurrence was calculated as 
the number of times the mutation was observed in all samples. The majority of unique 
somatic missense mutations, even in the likely driver genes, have a low recurrence (< 
5). Recurrence values were grouped into six bins, the last of which covers all 





average number of unique missense mutations per sample, observed in the samples of 
the corresponding cancer type. 
 
3.2.5 Analysis of structure disorder and surface missense mutations 
DISOPRED3.16 (Jones & Cozzetto, 2015) with default parameters was used to 
predict intrinsically disordered protein residues in each data set. STRIDE  
(Eisenhaber & Argos, 1993; Eisenhaber et al., 1995; Frishman & Argos, 1995) was 
used to calculate the absolute solvent accessible surface area (SASA) of each amino 
acid residue in the protein structures or homology models prepared as described in  
(Yue et al., 2005) and above.  The relative SASA was then calculated by normalizing 
the STRIDE results with the corresponding amino acid residue maximal solvent 
accessibility reported in (Rost & Sander, 1994). Based on the relative SASA, residue 
location was assigned as buried core (<0.05), partially exposed (≥0.05, ≤ 0.25), and 
surface (>0.25). The relative density (RD) of missense mutations in a particular state 
is calculated as follows: 




where, given two particular states 𝑖 and 𝑗 (disordered, ordered, buried in the core, and 
exposed on the surface), 𝑁𝑖 and 𝑁𝑗 are the total number of missense mutations in the 
corresponding states, and 𝑀𝑖 and 𝑀𝑗 are the total number of amino acid residues in 







3.3.1 Performance of variant interpretation methods on monogenic disease and cancer 
missense mutations 
I begin the analysis by investigating the fraction of monogenic disease mutations and 
assumed cancer drivers that are predicted to be deleterious by a number of sequence-
based methods. As noted earlier, these methods indirectly utilize the impact of a 
mutation on fitness. Figure 3-1A shows the results using three different sequence 
methods (SNPs3D profile (Yue & Moult, 2006), Polyphen2 (Adzhubei et al., 2010) 
and CADD (Kircher et al., 2014)), comparing the fraction of mutations predicted to 
be deleterious on a monogenic disease dataset, HGMD (Stenson et al., 2003) and 
mutations in two sets of cancer driver genes (Cancer Genome Atlas Network, 
Bainbridge, et al., 2012; Cancer Genome Atlas Network, Koboldt, et al., 2012; 
Cancer Genome Atlas Research Network et al., 2008, 2011, 2012; Cancer Genome 
Atlas Research Network, Getz, et al., 2013; Cancer Genome Atlas Research Network, 
Ley, et al., 2013; Forbes et al., 2017). These methods have previously been shown to 
be effective for identifying monogenic disease mutations (Dong et al., 2015; Yin, 
Kundu, Pal, & Moult, 2017; Yue et al., 2005), and consistent with that, the fraction 
predicted deleterious here is high, between 0.85 and 0.88. For all three methods, the 
fraction deleterious for mutations in cancer driver genes is substantially lower (0.64 - 
0.74) (Figure 3-1A). An additional four monogenic disease missense analysis 
methods and three developed specifically for cancer missense analysis show the same 
pattern (Table 3-2). Previous studies have also shown similar results for cancer data 





Figure 3-1B shows that in contrast to the results for the disease mutations, 
interspecies variants in these three sets of genes have a uniformly low predicted 
deleterious fraction (0.03 - 0.10), with no significant differences between monogenic 
disease and cancer. Although a low number of human monogenic disease mutations 
may be found to be fixed in other species (Kondrashov, Sunyaev, & Kondrashov, 
2002), these numbers do provide an approximate measure of the false positive rate for 
the methods. Surprisingly, for mutations in passenger genes (Figure 3-1C) the 
predicted deleterious fraction is much higher (34% to 82%) than for the interspecies 
variants in the driver genes. As discussed later, there are two possible factors 
contributing here: weak purifying selection in cancer samples (suggested by others 
(McFarland, Korolev, Kryukov, Sunyaev, & Mirny, 2013)), and additional drivers in 
genes currently designated as passengers. Table 3-3 provides the number of missense 

















Figure 3-1: Performance of three sequence-based variant interpretation methods on 
mutations in the two types of diseases. (A) Fraction of predicted deleterious 
mutations for monogenic disease mutations (HGMD, blue), cancer somatic mutations 
in the Sander driver gene list (TCGA Sander, green), and cancer somatic mutations in 
the COSMIC Cancer Gene Census driver gene list (COSMIC, red). A consistently 
high fraction of monogenic disease mutations appear deleterious, while the fractions 
of mutations in cancer driver genes are consistently lower. (B) Fraction of predicted 
deleterious interspecies variants in these gene sets. A very low fraction is predicted 
deleterious in all three data sets, supporting a low false positive rate for the methods. 
(C) Fraction of predicted deleterious mutations in passenger genes in the two cancer 
data sets. A surprisingly high fraction of mutations are predicted deleterious 
compared with the interspecies controls, suggesting limited purifying selection and 
the presence of additional driver mutations.  

































Table 3-3. Total number of mutations and genes (Italics in brackets) in each dataset, 







Ordered or disordered mutation subsets predicted by DISOPRED3 
b





3.3.2 The effect of passenger mutations in cancer driver genes 
A likely reason for the lower fraction of mutations predicted deleterious for cancer is 
that not all mutations in driver genes are drivers, for example, the mutations within 
the C-terminus in the APC protein (Vogelstein et al., 2013). I used two methods to 
identify subsets of mutations enriched in drivers. The first assumes that the more 
cancer samples a mutation is observed in, the more likely it is to be a driver, an 
approach that others have also used (Ciriello et al., 2013). Figure 3-2 shows the 
dependence of the predicted deleterious fraction (PDF) on the number of occurrences 
of a mutation. Strikingly, the PDF in driver genes increases sharply with mutation 
recurrence, from approximately 0.6 for mutations only observed once to 0.9 for those 
observed more than 10 times. The latter value is higher than the PDF for monogenic 
disease. For mutations in passenger genes, on the other hand, the PDF does not 
increase with recurrence and is lower than the lowest value for driver genes. Thus, by 
this criterion, the low PDF observed in the driver gene mutation set is primarily a 
consequence of the presence of passenger mutations in driver genes, and a pure driver 
set would have a PDF values as high as or higher than that for monogenic disease. 
 
The second method of enriching for driver mutations examines the PDF as a function 
of the average total mutational load in different cancer types. As noted above, 
mutational load differs by more than two orders of magnitude, depending on cancer 
type (Martincorena & Campbell, 2015; Vogelstein et al., 2013), so that the 
background of passengers in low mutation load cancers will be very much smaller 





overall PDF, the PDF will be higher in cancer types with a lower mutational load. 
Figure 3-3 shows that this is indeed the case: for driver genes, the trend is for 
increased PDF as mutation load decreases, whereas passenger genes show no trend. 
These results are consistent across three different variant interpreting methods (Figure 
3-4). Thus, by this criterion too, the low PDF observed in the driver gene mutation set 
is primarily a consequence of the presence of passenger mutations in driver genes. 
 
3.3.3 Other factors that may affect the fraction of driver gene mutations predicted deleterious 
I explored two other possible explanations for the different deleterious rates for 
monogenic disease and cancer mutations. One difference between the two types of 
disease is that whereas most monogenic disease missense mutations overwhelmingly 
result in loss of protein function (Yue et al., 2005), cancer driver mutations are either 
loss of function (in tumor suppressors) or gain of function (in oncogenes). I divided 
the cancer data into these two subtypes and repeated the analysis (Table 3-4). Results 
vary a little by methods, but overall there is no substantial difference between the two 
types of driver genes, so this is not a significant factor in the monogenic 
disease/cancer difference. A second possible explanation is training bias - methods 
trained on one type of disease may not perform as well on the other. Two lines of 
evidence show this is also not a significant factor. First, the analysis done with the 
three cancer-specific methods shows a similar monogenic disease/cancer difference 
(Table 3-2). Second, versions of the SNPs3D Profile method retrained on the cancer 
datasets also produce a lower predicted deleterious fraction in cancer genes than in 






Table 3-4. Performance of variant interpretation methods on cancer oncogene and 
tumor suppressor gene subsets 
Variant interpreting 
method 




Fraction of predicted 
deleterious mutations in 















SNPs3D Profile 0.66 0.68  0.75 0.70 
PPH2 0.72 0.72  0.77 0.73 
CADD 0.79 0.68  0.71 0.66 
SIFT 0.69 0.67  0.75 0.68 
LRT 0.87 0.82  0.73 0.75 
VEST3 0.88 0.83  0.87 0.83 
PROVEAN 0.60 0.59  0.60 0.57 
SNPs3D Stability 0.47 0.44  0.59 0.53 










 FATHMM 0.37 0.39  0.52 0.57 
MutationAssessor 0.52 0.45  0.53 0.49 
CHASM 0.75 0.80  0.71 0.80 











Figure 3-2: Fraction of predicted deleterious mutations in the driver genes (circles 
and solid lines) as a function of mutation recurrence, for two cancer datasets. The 
fraction rises from around 0.6 for single occurrence mutations to about 0.9 for those 
occurring more than 10 times.  In contrast to that, for passenger gene mutations 
(squares and dashed lines), the value is approximately constant for all recurrence 
values, and lower than for the lowest recurrence driver gene value. These data are 
consistent with an increase in the fraction of driver mutations with recurrence. For the 
most enriched driver set, the fraction predicted deleterious is higher than that for 
monogenic disease (Figure 3-1). The results are consistent across SNPs3D Profile 
(blue), PPH2 (green) and CADD (orange). Error bars show 95% confidence intervals 





Figure 3-3: (A) The fraction of predicted deleterious mutations in TCGA Sander 
driver genes is negatively correlated with the mutation load across cancer types, 
whereas (B) the fraction of predicted deleterious mutations in the TCGA passenger 
genes does not show correlation with the mutation load. The correlation is consistent 
across SNPs3D Profile (shown here), PPH2 (shown in Figure 3-4) and CADD 
(Figure 3-4). The results are consistent with the overall low predicted deleterious 
fraction arising from the burden of passenger mutations in driver genes. Error bars 
show 95% confidence intervals inferred from 100 rounds of bootstrapping. Small 
error bars may be obscured by symbols. BLCA: Bladder urothelial carcinoma; 
BRCA: Breast invasive carcinoma; COADREAD: Colon and rectum 
adenocarcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous 
cell carcinoma; KIRC: Kidney renal clear-cell carcinoma; LAML: Acute myeloid 














Figure 3-4: The fraction of predicted deleterious mutations derived with (A) PPH2 
and (C) CADD in driver genes in the TCGA Sander list are negatively correlated with 
the mutation burden across cancer types, whereas the fraction of predicted deleterious 
mutations in the TCGA passenger genes (B, D) show no or weak positive correlation 
with the mutation burden. These results are consistent with those from SNPs3D 
Profile (Figure 3). Error bars indicate the 95% confidence intervals inferred from 100 
round bootstrapping. Small error bars may not be obscured by the symbols. BLCA, 
Bladder urothelial carcinoma. BLCA: Bladder urothelial carcinoma; BRCA: Breast 
invasive carcinoma; COADREAD: Colon and rectum adenocarcinoma; GBM: 
Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KIRC: 
Kidney renal clear-cell carcinoma; LAML: Acute myeloid leukemia; LUAD: Lung 
adenocarcinoma; LUSC: Lung squamous cell carcinoma; OV: Ovarian serous 


























aFraction of missense mutations predicted deleterious or destabilizing 
bDisease related genes in HGMD, or the Sander list of diver genes in TCGA, or 
Cancer Gene Census (CGC) driver genes in COSMIC 
cCGC, Cancer Gene Census (COSMIC) 
dOG, Oncogenes 
eTS, Tumor suppressor genes 
fAfter removing collagen proteins 
gLow counts for this subset 
 
 
3.3.4 Intrinsically disordered regions in monogenic disease and cancer 
I next examine the first of three protein structure related factors that affect the 
properties of monogenic disease and cancer mutations: the role of intrinsically 
disordered structure. 27% of residues in monogenic disease proteins are predicted 
disordered by the method used here (Jones & Cozzetto, 2015) (Figure 3-5A).  Cancer 
passenger proteins, representing the majority of genes, have a similar value (Figure 3-
5A). But for cancer driver proteins, as others have also noted (Pajkos, Mészáros, 
Simon, & Dosztányi, 2012), the predicted content of disordered residues is 
substantially higher, at 40 to 45% (Figure 3-5A). (The disorder data are derived using 
a machine learning prediction method (Jones & Cozzetto, 2015) rather than direct 






Figure 3-5: (A) Predicted fraction of intrinsically disordered residues. Only about ¼ 
of monogenic disease protein residues are predicted disordered (blue), compared with 
nearly twice as many in cancer driver genes (green and red). Passenger gene values 
are close to those for monogenic disease. (B) Ratio of mutation density in disordered 
regions to that in ordered regions. The relative density of cancer driver mutations is 
more than twice as high as for monogenic disease. High passenger protein relative 
density and very high values for interspecies variants are consistent with lower 
functional restraints in disordered regions. (C) The fraction of mutations in disordered 
regions of cancer driver genes decreases with mutation recurrence rate, consistent 
with most mutations in these regions being passengers. No dependence on recurrence 
rate is seen for the equivalent mutations in passenger genes.  (D) The fraction of 
mutations in disordered regions of cancer driver proteins increases with cancer type 
mutational load, also consistent with most of these mutations being passengers. Error 
bars show 95% confidence intervals derived from 100 rounds of bootstrapping. Small 
error bars may be obscured by symbols. BLCA: Bladder urothelial carcinoma; 
BRCA: Breast invasive carcinoma; COADREAD: Colon and rectum 
adenocarcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous 
cell carcinoma; KIRC: Kidney renal clear-cell carcinoma; LAML: Acute myeloid 
leukemia; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; 













3.3.5 Mutations in intrinsically disordered regions 
Figure 3-5B shows that monogenic disease mutations are only ~1/3 as likely to occur 
at disordered positions as ordered ones. This, together with the low fraction of 
disordered residues, results in a total of only 10% of monogenic disease mutations 
lying in disordered regions, indicating a small role for these in this type of disease. In 
contrast to this, cancer driver gene mutations are only moderately less likely in 
disordered regions than in ordered ones (0.76), and that, together with the higher 
content of disorder in cancer driver proteins, results in total 31~34% of these 
mutations occurring in disordered regions. Two factors may contribute to the higher 
disorder cancer mutation density - an excess of passenger mutations in disordered 
regions, and a possible greater functional role for disordered regions in cancer drivers 
than in monogenic disease. Figure 3-5B also shows that the density of mutations in 
the ordered and disordered regions of passenger proteins is approximately equal and 
slightly higher than that of driver proteins and that the highest relative density is for 
interspecies variants, with a density more than 2.5 times higher in disordered regions 
than ordered ones. Both this and the higher passenger relative density are consistent 
with substantially less functional restrictions on the acceptance of mutations in 
disordered regions and so a tendency for passengers to accumulate there. In support 
of this, Figure 3-5C shows that the fraction of driver gene mutations observed more 
than 10 times (and therefore most likely to drivers) in disordered regions is only 1/3 
the fraction for mutations observed only once (so least likely to be drivers). Similarly, 





decreasing total mutational load, consistent with a higher fraction of passengers in 
these regions.  
 
3.3.6 Fraction of deleterious mutations in ordered and disordered regions 
I next examine predicted deleterious rates in disordered versus ordered regions, using 
the sequence methods introduced earlier. Since all sequence methods are trained on a 
full set of disease mutations, and, particularly for monogenic disease, there are more 
mutations in ordered than disordered regions, training bias was a concern here. To 
investigate the extent of bias, I trained versions of the SNPs3D profile method on 
only disordered HGMD mutations together with disordered interspecies variants as 
controls and also trained on the corresponding ordered data. In fact, retraining made 
almost no difference to the results: the predicted deleterious fraction (PDF) in ordered 
regions is unchanged at 0.85. The original PDF in disordered regions is 0.86 and for 
the retrained method is 0.84.  Correction for a second factor does have a significant 
impact on the results. Inspection of the set of HGMD mutations in disordered regions 
revealed that a substantial fraction (438 out of the total of 1110) are in collagen. At 
first glance, it seems odd that collagen should be classed as a disordered protein, but 
this is a correct characterization - the bulk of collagen molecules are formed from a 
homo-triple helix. A hypothetical monomer would be structurally disordered, and the 
repeat triplet of the sequence is one of the possible signatures of disordered regions. 
Nevertheless, from the point of view of this analysis, the collagen mutations are 
atypical of disordered regions in other proteins, so I again retrained the SNPs3D 





collagen mutations, is now substantially lower (0.69 versus 0.84). Figure 3-6A shows 
that result on monogenic disease mutations together with those from Polyphen2 
(Adzhubei et al., 2010) and CADD (Kircher et al., 2014), omitting the collagen 
mutations. The results from all three methods are similar and show consistently lower 
PDFs for disordered versus disordered regions (0.85 - 0.89 in ordered regions, 0.69 - 
0.68 in disordered regions). That is, for monogenic disease, the fraction of mutations 
predicted deleterious is about 20% lower for disordered than ordered regions. The 
reason for this is unclear, but it is likely that the feature sets used in the sequence 
methods are not an optimal choice for disordered regions, and result in a higher false 
negative rate. If so, this will depress the values for cancer mutations in disordered 
regions as well.  
 
Indeed, Figure 3-6B shows that the fraction of driver gene mutations predicted 
deleterious in disordered regions is consistently about 30% lower than in ordered 
regions.  The difference here is larger than for monogenic disease (30% versus 20%), 
suggesting that even after allowing for the apparent high false negative rate in 
disordered regions, these may contain a lower fraction of driver mutations than 
ordered regions, consistent with the results in Figure 3-5.  
 
Figure 3-6: (A) The fraction of predicted deleterious mutations is approximately 20% 
lower in disordered regions of monogenic disease proteins than in ordered regions. 
(B) For cancer driver proteins, the fraction of predicted deleterious mutations in 





of predicted deleterious mutations in the ordered (circles and solid lines) and 
disordered (square and dashed lines) regions of COSMIC Cancer Gene Census driver 
proteins as a function of mutation recurrence. For mutations with low recurrence, the 
fraction of predicted deleterious mutations is consistently lower in disordered regions 
than in ordered regions. Both fractions rise as a function of mutation recurrence and 
converge when mutations are observed for more than 10 times. Error bars show 95% 
confidence intervals derived from 100 rounds of bootstrapping.  





3.3.7 Other properties of mutations in disordered versus ordered regions 
We found no tendency for tumor suppressors and oncogenes to be differently 
distributed between disordered and ordered regions. Similarly, we found no tendency 
for monogenic disease mutations in genes classified as dominant versus recessive to 
be differently distributed in disordered and ordered regions.  
 
3.3.8 Protein surface and core mutations 
A second structural feature that provides insight into the mutation properties is the 
fraction of mutations on the surface of proteins versus in the core. Figure 3-7A shows 
that the fraction of all residues designated ‘surface’ (using STRIDE (Eisenhaber & 
Argos, 1993; Eisenhaber et al., 1995; Frishman & Argos, 1995), see Methods) is 
similar for all categories of protein, at approximately 50% (See Figure 3-8A for the 
mutations in the core). As shown in Figure 3-7B, the relative density of monogenic 
disease mutations on the surface to that in the core is only 0.58, showing a strong 
tendency for mutations in this class of disease to be buried (See Figure 3-8B for the 
mutations in the core).  In contrast to this, both cancer driver gene sets show an 
enrichment of 1.3 for mutations on the surface versus in the core. Passenger gene 
mutations show a larger surface enrichment of 1.75 on average, and by far the highest 
surface enrichment is for inter-species variants, 3.6 to 4.2. The latter values reflect the 
fact that there are more possible neutral mutations on the surface than in the interior, 
so substitutions are more likely to be fixed on the surface, and there are more 
opportunities for benign passenger mutations there as well. We therefore expect some 





accumulation of passengers. However, unlike the data for disordered regions, the 
fraction of driver gene mutations on the surface as a function of mutation recurrence 
does not show a significant trend (Figure 3-7C) and so does not support an excess of 
surface passengers. Interpretation of this plot is complicated by a strong tendency for 
oncogene mutations to be on the surface and tumor suppressors to be in the core (see 
below). Since oncogene mutations have a higher recurrence rate than tumor 
suppressors, that tendency will dampen any relationship between surface and 
recurrence.  (The corresponding surface density versus mutation load plot does show 
the expected relationship, but because of limited structural data, 95% confidence 
limits are large - data not shown). An alternative probe of the extent of passengers in 
surface regions is to consider the fraction of surface mutations predicted deleterious 
as a function of recurrence, since this fraction is similar for tumor suppressors and 
oncogenes (Table 3-5). Figure 3-7D shows a strong trend of increasing deleterious 
rate with mutation recurrence, consistent with the results from the passenger proteins 
and interspecies variant density results. Overall, the data support the conclusion that a 
substantial part of the excess surface mutations in cancer driver proteins are passenger 
mutations. 
 
 I also examined the surface to core distribution for mutations in oncogenes and tumor 
suppressors (Figure 3-9). Unlike the corresponding data for disorder/order, there is a 
marked difference in surface enrichment for the two classes of genes: for oncogenes 
the density of surface mutations is 1.9 times that of core mutations, while for tumor 





the core). For monogenic disease, there is also a smaller but still significant difference 
between the surface to core densities for genes classified as dominant and those 






Figure 3-7: (A) For all classes of protein, about half of all residues are designated 
surface. (B) Ratio of mutation density on the surface to that in the core. The density 
of monogenic disease mutations on the surface is only about ½ that in the core, 
whereas for cancer driver protein mutations the density is higher on the surface.  High 
ratios for interspecies variants and passenger proteins are consistent with less 
functional constraints on surface residues. (C) The fraction of surface mutations in 
cancer driver genes does not significantly correlate with mutation recurrence, so does 
not support an excess of surface mutations being passengers. A confounding factor is 
the tendency for oncogene mutations to be on the surface. (D)  Fraction of predicted 
deleterious mutations in the core (circles and solid lines) and on the surface (square 
and dashed lines) for COSMIC Cancer Gene Census driver proteins as a function of 
mutation recurrence. The fraction of predicted deleterious mutations on the surface 
rises from around 0.7 for single occurrence mutations to 0.8~0.9 for those occurring 
more than 10 times. Error bars show 95% confidence intervals derived from 100 
















Figure 3-8 (A) Fractions of core residues and (B) ratio of mutation density in the core 
to that on the surface in monogenic disease genes and cancer driver genes, in the 
corresponding interspecies variants datasets, and in cancer passenger genes. The 
density ratio in HGMD disease genes is significantly higher than in the cancer driver 
genes. Compared to Figure 6, interspecies variants and somatic mutations in the 
passenger genes are more enriched on the protein surface, which supports that surface 
















Figure 3-9 (A) The relative residue fraction and (B) the relative mutation density, and 
(C) the fraction of mutations predicted destabilizing using the SNPs3D Stability 
method for core and surface mutations in the TCGA Sander oncogene set, the TCGA 
Sander tumor suppressor gene set, the COSMIC Cancer Gene Census oncogene set, 
and the COSMIC Cancer Gene Census tumor suppressor gene set. Missense 
mutations are enriched in the core in tumor suppressor genes, and on the surface in 
oncogenes. In the core, the fraction predicted deleterious by SNPs3D Stability 





3.3.9 Role of structure destabilization 
I next examine the role of structure destabilization in cancer mutations compared to 
those in monogenic disease. As noted earlier, destabilization plays a major role in 
monogenic disease mechanisms (Yue et al., 2005) and our earlier analysis suggests a 
significant role in cancer too (Shi & Moult, 2011). For this purpose, I trained separate 
stability SVMs on surface and core monogenic disease mutations, with interspecies 
variants in those regions as controls. Figure 3-10A shows that overall 0.71 of 
monogenic disease mutations are predicted to be destabilizing (similar to the value 
Yue & Moult reported earlier (Yue & Moult, 2006)), whereas only about 0.50 to 0.53 
cancer driver gene mutations are predicted destabilizing, a large difference. The 
interspecies variant results provide an estimated false positive rate of 0.15. To address 
possible bias arising from training the stability method on monogenic disease data, I 
retrained using cancer data. This model was unsatisfactory in that it delivered much 
higher false positive rates (0.24 to 0.41 of interspecies variants predicted 
destabilizing, Table 3-5), but the relationship between the fraction of monogenic 
disease mutations predicted destabilizing and the fraction for cancer driver genes is 
similar to that obtained with the monogenic disease model (0.81-0.84 for monogenic 
disease and 0.64-0.68 for cancer driver gene mutations, Table 3-5), supporting the 
conclusion that destabilization rates are substantially higher for monogenic disease 
than for cancer driver gene mutations. 
 
Based on the other analyses, we expect that passenger mutations in driver genes are 





fraction of destabilizing mutations as a function of mutation recurrence (Figure 3-
10D) supports a role for this factor, although less strongly than in the corresponding 
sequence analysis. A second contribution to different levels of destabilization in 
cancer and monogenic disease may come from the higher proportion of surface 
mutations in cancer: surface mutations are intrinsically less likely to be destabilizing. 
To help isolate this effect, I examined the role of destabilization in surface and core 
mutations separately. As expected, values for surface and core are markedly different: 
For monogenic disease, 0.76 of mutations in the core are predicted destabilizing, 
compared with 0.63 for surface. For cancer driver gene mutations, average values are 
0.63 for core and 0.42 for surface (Figure 3-10B).  
 
We expected that the distinction between surface and core destabilization properties 
might be particularly sensitive to whether a mutation is an oncogene or a tumor 
suppressor, so also examined the surface/core properties of these two classes 
separately. Indeed, tumor suppressor destabilizing fractions are higher in the core 
than those for oncogenes (0.73/0.67 versus 0.59/0.53), while surface values are 
similar for the two classes of mutation (Table 3-5, Figure 3-9). Thus, particularly for 
tumor suppressor mutations, a high (>70%) fraction of core mutations in both 












Figure 3-10: Fraction of predicted destabilizing mutations. (A) More than 70% of 
monogenic disease mutations are predicted destabilizing compared with only about 
half of mutations in cancer driver genes. The value for passenger gene mutations is 
not much lower than for driver genes. (B) The predicted destabilizing fraction is 
substantially lower on the surface than in the core for both types of disease. (C) 
Dependence on the fraction of mutations predicted destabilizing on the fraction of 
surface mutations. Each point is for one gene. The fewer mutations on the surface, the 
higher the fraction that predicts destabilizing, and monogenic disease genes (blue) 
tend to have a lower surface fraction than cancer genes. (D) Relationship between the 
fraction predicting deleterious and recurrence for cancer mutations. The driver gene 
destabilizing fraction increases with recurrence, consistent with a mixture of driver 
and passenger mutations in these genes. There is no trend for passenger gene 
mutations. Results are for SVMs trained on monogenic disease surface and core 
mutations separately. Error bars show 95% confidence intervals derived from 100 













In this paper, I have used computational methods together with sequence and 
structure information to investigate and compare the properties of missense mutations 
causative of monogenic disease and driving cancer. The principal findings are as 
follows: 
 
3.4.1 Most monogenic disease and cancer driver mutations are under selection pressure, and 
so can be identified with sequence-based methods 
After allowing for the effects of passenger mutations in cancer driver genes, I find a 
high fraction (> 80%) of mutations causing monogenic disease and of cancer driver 
mutations are predicted to be deleterious. These results are consistent across three 
different methods trained on monogenic disease (Figures 3-3, Figure 3-4). There are 
two primary implications. First, sequence methods trained on monogenic disease data 
are effective at identifying cancer drivers. Second, the large majority of mutations 
positions in both types of disease are under strong selection pressure (otherwise the 
sequence methods used would not be effective). While this was likely for most 
monogenic diseases, which are often severe and early onset, it is less obvious for 
cancer mutations, selected within a clone primarily to promote cell growth. It is not 
yet clear what fraction of the apparent false negatives - disease mutations not 







3.4.2 Mutations in disordered regions play a limited role in both monogenic disease and 
cancer 
Figure 3-5A shows that there is a much higher involvement of disordered regions in 
cancer than in monogenic disease, with only 10% of monogenic disease mutations in 
these regions, compared with 31-34% of cancer driver protein mutations. Two factors 
contribute to this difference. First, cancer driver genes are unusual in containing 
almost three times as much disorder as monogenic disease genes or passenger genes. 
That higher disordered fraction likely reflects a different functional spectrum for 
these proteins. In particular, it has been noted that these proteins are more hub-like 
(Goh et al., 2007; Jonsson & Bates, 2006; Kar, Gursoy, & Keskin, 2009) (involved in 
interactions with many partners), perhaps implying that more disordered regions are 
required to provide specificity for a range of protein binding partners (Fornili, 
Pandini, Lu, & Fraternali, 2013; J. Liu, Faeder, & Camacho, 2009). For example, the 
intrinsically disordered terminal trans-activation domain of P53 binds to three 
different protein partners in three different conformations (Oldfield et al., 2008). 
Second, the relative density of driver protein mutations in these regions is twice as 
high as for mutations in monogenic disease genes (~0.64 versus 0.30). However, the 
even higher relative mutation density in passenger protein disordered regions (~0.9) 
and for interspecies variants (~2.6) suggests that part of the cancer excess density is a 
consequence of benign passenger mutations being more likely to lie in disordered 
regions. Analysis of the relative densities as a function of the mutation recurrence and 
cancer mutational load confirm this is the case. The fraction of mutations predicted 





that for monogenic disease, also consistent with a high fraction of passengers in these 
regions (Figure 3-6). As noted above, the apparently deleterious mutations in 
disordered regions may often be involved in protein-protein interactions. The extent 
to which disordered regions of proteins are involved in function has not been clear 
(Vacic et al., 2012). Two aspects of these results confirm that disordered regions are 
much less functionally significant - the very low fraction of monogenic disease 
mutations there, and the high concentration of interspecies variants and passenger 
mutations. 
 
3.4.3 Cancer oncogene mutations tend to be on the protein surface, whereas monogenic 
disease mutations and tumor suppressors tend to be in the core 
The surface density of mutations in cancer driver genes is higher than in the core, and 
for mutations in oncogenes, it is nearly twice as high. While some of this difference 
reflects excess passenger mutations on the surface, it also likely reflects the greater 
role for disruption of intermolecular interactions in cancer (Nishi et al., 2013) and 
also that gain of function oncogene mutations tend to affect surface processes such as 
kinase conformational states related to phosphorylation (Blume-Jensen & Hunter, 
2001). Conversely, tumor suppressor mutation density is higher in the core than on 
the surface, and for monogenic disease mutations, the core density is twice that of the 
surface. As discussed below, these values reflect the high role of structure 
destabilization for these classes of mutation. In monogenic disease, there is a higher 
relative density of surface mutations in autosomal dominant genes than recessive ones 





disease, including haplo-insufficiency, oligomer structure (of which collagen 
mutations are an example (Lamandé et al., 1998)), and gain of function. The latter 
mechanism likely contributes most to the surface/core signal, in a manner analogous 
to that of gain of function mutations in oncogenes. Examples are of monogenic 
surface gain of function mutations in the calcium sensing receptor (CASR), causing 
hypocalcemia, and in Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR), 
causing Familial Male-Limited Precocious Puberty (FMPP). 
 
3.4.4 A large fraction of monogenic disease and cancer tumor suppressor mutations in the 
protein core destabilize protein structure 
Approximately ¾ of both monogenic disease mutations and cancer tumor suppressor 
mutations in the protein core are predicted to destabilize protein structure. A 
prediction of destabilization using this method is equivalent to a major decrease in 
protein abundance in vivo (Yue et al., 2005), either through misfolding or reduced 
protein half-life. Most monogenic disease missense mutations result in a major loss of 
molecular function (for example, (Shi, Sellers, & Moult, 2012) and (Yin, Kundu, Pal, 
& Moult, 2017)). To the extent that core tumor suppressor mutations can be 
considered to represent all driver mutations, the result implies that in this class of 
disease too there is usually major loss of protein function, rather than a subtle effect at 
that level.  
 
What about the other 25% of core monogenic mutations and tumor suppressor 





effect on protein function? Recessive mutations provide some evidence here, since a 
disease outcome for most of these involves a 50% or greater loss of molecular 
function. The predicted destabilization fraction for the recessive mutations is 
approximately the same as for monogenic disease as a whole. That suggests that most 
of the remaining 25% are a combination of false negatives of the computational 
method and mechanisms other than destabilization, rather than mutations with a 
subtle effect on function.  
 
There are some oncogene mutations in the core region, and about 50% of these are 
predicted to destabilize protein structure, at first glance a surprising result, since these 
should be gain of molecular function. As noted earlier, less than 1/3 of oncogene 
mutations are in the core, so that a 50% destabilization rate corresponds to just 1/6 of 
oncogene mutations. The estimated false positive rate is 0.15, close to that value, and 
there may be some cases where oncogene gain of function is the result of 
destabilization of a regulatory domain. Also, the definition of oncogenes and tumor 
suppressors is not always unambiguous. In compiling the oncogene and tumor 
suppressor lists I noted that 10 genes had been classified as oncogenes by one group 
and tumor suppressors by the other (these were excluded). There are also examples 
where a gene may behave as an oncogene in some circumstances and a tumor 






3.4.5 Mutations in passenger genes show a high fraction of deleteriousness 
A surprisingly high fraction (more than 50%) of mutations in passenger genes appear 
deleterious with the sequence methods used here. The estimated false positive rate is 
much lower (10% or less). Stability analysis supports this observation, with almost as 
high a fraction of passenger gene mutations predicted destabilizing as in driver genes. 
There are at least two possible explanations. One is that there is insufficient selection 
pressure to eliminate these mutations in a typical cancer. Simulations of cancer 
progression suggest that moderately deleterious mutations will escape elimination by 
various population genetics mechanisms, and so accumulate, sometimes impending 
cancer progression (McFarland et al., 2013). The other is that there is a significant 
concentration of unrecognized driver genes. As noted earlier, there is considerable 
variation in driver set definitions, so that it is expected this would be the case to some 
degree. But depending on the cancer type and particular case (Martincorena & 
Campbell, 2015), there may be up to 100s or even a thousand deleterious mutations 
spread across non-driver genes and a deleterious fraction of 0.5 implies that a 
substantial fraction of these mutations genes must be drivers or deleterious mutations 
not yet selected out, which seems improbable. The exact nature and impact of these 
mutations will repay further study. 
 
In common with all analyses so far we have assumed a binary model of cancer drivers 
- a mutation is either a driver or not. But it may be that there is a continuous scale of 





contributions, loosely analogous to the contributions of variants to complex trait 
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4.1 Abstract 
Endolysins are bacteriophage-derived peptidoglycan hydrolases that represent an 
emerging class of proteinaceous therapeutics. While the streptococcal endolysin PlyC 
has been validated in vitro and in vivo for its therapeutic efficacy, the inherent 
thermosusceptible structure of the enzyme correlates to transient long-term stability, 
thereby hindering the feasibility of developing the enzyme as an antimicrobial. Here 
we thermostabilized the CHAP domain of the PlyCA catalytic subunit of PlyC using 
a FoldX-driven computational protein engineering approach. Using a combination of 
FoldX and Rosetta algorithms, as well as visual inspection, a final list of PlyC point 
mutant candidates with predicted stabilizing ΔΔG values was assembled and 
thermally characterized. Five of the eight point mutations were found experimentally 





complex and dynamic nine-subunit holoenzyme with a corresponding 3.3-Å X-ray 
crystal structure. However, one of the mutants, PlyC (PlyCA) T406R, was shown 
experimentally to increase the thermal denaturation temperature by ~2.2°C and 
kinetic stability 16 fold over wild-type. This mutation is expected to introduce a 
thermally advantageous hydrogen bond between the Q106 side-chain of the N-
terminal GyH domain and the R406 side-chain of the C-terminal CHAP domain. 
 
4.2 Introduction 
Endolysins, also termed phage lysins or enzybiotics, are bacteriophage-encoded 
peptidoglycan hydrolases (Nelson et al., 2006). During a lytic bacteriophage (phage) 
replication cycle within the host bacterium, endolysins are expressed and accumulate 
in the cytosol in a fully folded and active conformation. The exact moment of cell 
lysis is then highly regulated by holins, hydrophobic membrane proteins that generate 
pore-forming complexes on the cytoplasmic membrane, providing cytosolic 
endolysins access to their peptidoglycan substrate (I. N. Wang, Smith, & Young, 
2000; Young, 1992). The endolysin then degrades the peptidoglycan upon direct 
contact due to the hydrolysis of key covalent bonds within the cell wall structure, 
resulting in osmotic lysis and liberation of intracellular progeny virions. With this 
mechanistic understanding, the exogenous application of a purified recombinant 
endolysin to susceptible Gram-positive bacteria produces the same bacteriolytic 
phenotype without the presence of the bacteriophage or holins and thus represents an 
alternative antimicrobial to treat antibiotic-resistant bacterial infections (Fischetti, 





PlyC is an endolysin derived from the streptococcal C1 lytic phage that has been 
validated in vitro for its bacteriolytic efficacy against groups A (GAS), C (GCS) and 
E (GES) streptococci and in vivo for its ability to protect mice from streptococcal 
challenge (Krause, 1957; Nelson et al., 2001). When added to GAS (Streptococcus 
pyogenes) in vitro, 10 ng of PlyC was able to cause a 7 log decrease in colony 
forming units in 5 s, making this endolysin ~100 fold more active than any other 
characterized endolysin to date (Nelson et al., 2001). Unlike other endolysins, which 
are single gene products consisting of one or more enzymatically active domains 
(EAD) and a cell wall binding domain (CBD), PlyC consists of a novel multimeric 
structure with nine distinct subunits (McGowan et al., 2012; Nelson et al., 2006). 
Eight identical PlyCB monomers interact to form a symmetrical octameric ring 
structure that serves as the CBD of the holoenzyme. The ninth subunit, PlyCA, 
functions as the EAD of the endolysin and consists of three domains. The 
catalytically-active N-terminal glycosyl hydrolase (GyH) and C-terminal cysteine, 
histidine-dependent amidohydrolase/peptidase (CHAP) domains act together 
synergistically to generate the robust bacteriolytic mechanism of the enzyme, whereas 
the central helical docking domain interacts with the PlyCB CBD to promote the 
formation of the holoenzyme structure (McGowan et al., 2012).  
 
Thermal denaturation of PlyC by means of differential scanning calorimetry (DSC) 
showed that the PlyCB octamer is endogenously thermostable, displaying a thermal 
transition temperature (TG) of 75.0°C, whereas the PlyCA EAD is thermosusceptible, 





the PlyCB octamer into isolated monomers is a reversible thermodynamic process, 
the unfolding of the individual PlyCA and PlyCB monomers is an irreversible event, 
which is supported by their inability to refold after being heat-denatured. The C-
terminal CHAP domain of PlyCA was shown to have a TG of 39.1°C when isolated, 
compared to a TG of 46.0°C associated with PlyCAΔCHAP in a PlyCΔCHAP 
background (i.e. PlyC holoenzyme with a PlyCA C-terminal CHAP domain deletion), 
suggesting that the CHAP domain of PlyCA is the most heat-labile structural 
component of the PlyC holoenzyme.  
 
Although the number of thermodynamically characterized endolysins is limited, there 
are examples of endolysins that display similar structural instability to that of PlyC. 
For example, the Staphylococcus aureus endolysin LysK as well as the Streptococcus 
pneumoniae endolysins Cpl-1, Pal and Cpl-7 are devoid of activity or unfold at 
42.5°C, 43.5°C, 50.2°C and 50.4°C, respectively (Bustamante, Rico-Lastres, Garcia, 
Garcia, & Menendez, 2012; Filatova, Becker, Donovan, Gladilin, & Klyachko, 2010; 
Sanz, Garcia, Laynez, Usobiaga, & Menendez, 1993; Varea et al., 2004).  In 
congruence to the Arrhenius equation, the thermolability of PlyC and other 
endolysins correlates to a short-term therapeutic shelf-life expectancy (Anderson & 
Scott, 1991).  
 
A number of computational methods have proven partially effective at identifying 
single amino acid substitutions that result in increased thermodynamic stability of a 





Parthiban, Gromiha, Hoppe, & Schomburg, 2007; Parthiban, Gromiha, & Schomburg, 
2006; Schymkowitz, Rousseau, et al., 2005; Zhou & Zhou, 2002). One example is 
FoldX (Guerois et al., 2002; Schymkowitz, Borg, et al., 2005; Schymkowitz, 
Rousseau, et al., 2005), which uses an empirical potential derived from a weighted 
combination of physical energy terms (e.g. van der Waals interactions, hydrogen 
bonding, electrostatics and solvation), statistical energy terms and structural 
descriptors. In third-party testing, FoldX has been shown to perform with useful 
accuracy across all protein structure types, yielding a correlation coefficient of 0.5 
between estimated and experimental ΔΔG (Khan & Vihinen, 2010; Potapov, Cohen, 
& Schreiber, 2009). Rosetta was developed primarily for designing proteins with 
desirable properties, including new protein folds (Brian Kuhlman et al., 2003), novel 
enzymatic activity (Jiang et al., 2008; Röthlisberger et al., 2008) and modified 
substrate specificity (Ashworth et al., 2006). The ddG module of Rosetta also 
provides a means of estimating ΔΔG for point mutations (Kellogg et al., 2011).  
 
Here we aim to engineer enhanced stability of a thermolabile bacteriolytic enzyme 
using computational modeling. Using the PlyC holoenzyme structure as the template, 
our engineering strategy was to apply the FoldX and Rosetta algorithms together, in 
addition to subsequent visual inspection, to the C-terminal CHAP domain of PlyCA. 
By doing so, we were able to identify one point mutant, PlyC (PlyCA) T406R, which 
was shown experimentally to thermostabilize the PlyC holoenzyme structure and 






4.3 Materials and methods 
4.3.1 Computational Modeling of PlyC Mutants 
Initial atomic coordinates were taken from the PlyC holoenzyme X-ray crystal 
structure (Protein Data Bank ID 4F88). Due to the relatively low 3.3-Å resolution of 
the structure, polypeptide backbones and side-chains were adjusted using Rosetta 
Relax (Raman et al., 2009), followed by another round of side-chain orientation 
optimization using the FoldX3.0 RepairPDB command (Guerois et al., 2002; 
Schymkowitz, Borg, et al., 2005). The resulting coordinates were then processed with 
FoldX3.0 PositionScan to obtain estimated changes in folding free energy (ΔΔGFoldX) 
for all of the 2,945 possible CHAP domain point mutants (155 total CHAP domain 
residues multiplied by the 19 alternative natural amino acids). The structural 
environments of those mutations with a predicted ΔΔGFoldX ≤ -1 kcal/mol were then 
manually inspected to remove those judged likely to introduce unfavorable structural 
alterations. Finally, the remaining mutants were processed through the Rosetta 
ddg_monomer application (Kellogg, Leaver-Fay, & Baker, 2011) to yield the PlyC 
candidate mutant list for experimental study.   
 
4.3.2 Bacterial Strains and Culture Conditions 
S. pyogenes D471 (group A streptococcus) was maintained and grown in Todd Hewitt 
broth supplemented with 1% yeast extract as previously described (Nelson et al., 
2001; Nelson, Schuch, Zhu, Tscherne, & Fischetti, 2003). E. coli strains DH5α and 





shaking incubator unless otherwise stated. When needed, ampicillin (100 μg/ml) was 
added to the media. 
 
4.3.3 Cloning and Site-directed Mutagenesis 
The plyC operon was cloned into pBAD24 as previously described (Nelson et al., 
2006). Site-directed mutagenesis was performed using the Phusion Site-Directed 
Mutagenesis Kit (Thermo Scientific). Mutations were introduced into the middle of 
the 30 nucleotide forward phosphorylated oligonucleotide primer for each mutant, 
with the reverse primer being complementary to the next 30 nucleotides upstream 
(Eurofins Scientific). The standard 50 µl PCR reaction mixture consisted of 1 ng of 
pBAD24::plyC, 1x Phusion HF Buffer, 0.2 mM dNTP, 0.5 μM of each primer and 1 
U of Phusion DNA polymerase. The thermocycler heating conditions consisted of 
98°C for 30 s, 25x (98°C for 10 s; 65°C for 30 s; 72°C for 4 min) and 72°C for 5 min. 
The resulting PCR products were then ligated and transformed into E. coli DH5α. 
Plasmid DNA was extracted from successful transformants and mutations were 
confirmed by nucleotide sequencing (Macrogen USA). Vector constructs comprising 
an insert with the correct nucleotide sequence were transformed into E. coli 
BL21(DE3)pLysS for protein expression. 
 
4.3.4 Protein Expression and Purification 
E. coli BL21(DE3)pLysS harboring the wild-type and mutant pBAD24::plyC 





ampicillin in a 4L baffled Erlenmeyer flask. Protein expression was induced with 
0.25% L-arabinose at 37°C overnight. The cells were harvested the following 
morning at 7,000 RPM, resuspended in phosphate buffered saline (PBS), pH 7.25, 
supplemented with 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich) and 
sonicated on ice for 15 min. The insoluble cell debris from the cell lysate was pelleted 
at 13,000 RPM for 1 h at 4°C. The soluble endolysins were then purified as 
previously described (Nelson et al., 2001). Protein solubility and purity were assessed 
on a 4-15% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) gel (Laemmli, 1970).  
 
4.3.5 In Vitro Endolysin Activity on S. pyogenes 
Spectrophotometric-based turbidity reduction assays were performed to determine the 
bacteriolytic activity of each endolysin investigated. An overnight culture of S. 
pyogenes D471 was harvested at 4,000 RPM for 15 min, washed once with PBS, pH 
7.2, and resuspended to an OD600 = 2.0. In a flat-bottomed 96-well plate, the purified 
endolysin at an initial concentration of 8.84 µM (1 mg/ml) was serial diluted in 100 μl 
of PBS buffer. An equal volume of bacteria was then mixed with the different 
enzyme concentrations and the OD600 was monitored kinetically on a SpectraMax 190 
microplate spectrophotometer (Molecular Devices) every 6 s for 30 min at 37°C. The 
amount of time (s) to decrease the initial OD600 by 50% was then plotted against the 
enzyme molar concentration and fit with a one-phase exponential decay curve. 1 U of 





ODmax by 50% in 15 min. Each independent turbidity reduction assay was performed 
in triplicate. 
 
4.3.6 Circular Dichroism Spectroscopy 
A Chirascan CD spectrometer (Applied Photophysics) equipped with a 
thermoelectrically controlled cell holder was used for all CD experiments. For 
secondary structure far-ultraviolet (UV) analysis, the endolysins were at a 0.1 mg/ml 
concentration in 20 mM sodium phosphate buffer, pH 7.0. CD spectra were obtained 
in the far-UV range (190-260 nm) in a 1 mm path length quartz cuvette at 1 nm steps 
with 5-second signal averaging per data point. Spectra were collected in triplicate, 
followed by averaging, baseline subtraction, smoothing and conversion to mean 
residue ellipticity (MRE) by the Pro-Data software (Applied Photophysics). 
Secondary structure prediction was performed using the Provencher and Glockner 
method provided by DICHROWEB (Provencher & Glockner, 1981; Whitmore & 
Wallace, 2004). Melting experiments were performed by heating the endolysins at a 1 
mg/ml concentration in 20 mM sodium phosphate buffer, pH 7.0, from 20°C to 95°C 
at 1°C/min. MRE was monitored at 222 nm in a 1 mm path length quartz cuvette at 
0.5°C steps with 5-second signal averaging per data point. The melting data was 
smoothed, normalized and fit with a Boltzmann sigmoidal curve. The first derivative 
of the melting curve was then taken to determine the temperature, TG, at which the 
concentration of the folded and unfolded states of the PlyCA subunit were the same. 






4.3.7 Differential Scanning Calorimetry 
DSC experiments were performed on a Nano DSC differential scanning calorimeter 
(TA Instruments) at a constant pressure of 3 atm.  All samples were degassed for at 
least 15 minutes prior to the experiment. The sample and reference cells consist of an 
optimal operational volume of 0.3 ml and were calibrated with equal volumes of 20 
mM sodium phosphate buffer, pH 7.0, by means of three consecutive heating/cooling 
cycles from 15°C to 105°C and 105°C to 15°C at 1°C/min. The endolysins were then 
heated from 15°C to 105°C at a 1°C/min heating rate in 20 mM sodium phosphate 
buffer, pH 7.0, using a final protein concentration of 1 mg/ml followed by immediate 
cooling from 105° to 15°C at 1°C/min. Data analysis by means of baseline 
subtraction and curve fitting was performed by the NanoAnalyze software (TA 
Instruments). Due to a scan rate-independence displayed by PlyC during calorimetric 
analysis (F. Schwarz, personal communication), equilibrium thermodynamics were 
applied to the finalized calorimetric dataset. The thermal transition temperature, TG, 
was defined as the mid-point of each thermal transition. 
 
4.3.8 45°C Kinetic Stability Assay 
The various endolysins investigated were incubated in a 45°C hot plate in PBS, pH 
7.2, at a 44 nM (5 μg/ml) concentration for a total of 3 hours. At 20 minute 
increments, a 400 μl aliquot of the heated enzyme was removed and incubated on ice 
for 5 minutes. Three adjacent wells of a 96-well plate were then filled with 100 μl of 
the cooled enzyme, followed by the addition of an equal volume of S. pyogenes D471 





lytic activity of the endolysin was analyzed via turbidity reduction assay by 
monitoring the OD600 every 6 s for 20 min. The activity of the endolysin was equated 
to the Vmax (milli-OD units per min) corresponding to the linear portion of the 
resulting killing curve. Residual lytic activity was normalized to the activity displayed 
in the absence of heat treatment.  
 
4.4 Results 
FoldX was applied to the C-terminal CHAP domain of PlyCA (CHAP is comprised 
of PlyCA amino acids 309-465; however, atomic coordinates were only available for 
residues 310-464), substituting each of the possible 19 alternative natural amino acids 
at each residue position, so generating a library of 2,945 PlyC mutants. Most of the 
mutations analyzed (n = 2,453) were predicted by FoldX to have either destabilizing 
or neutral effects on stability, resulting in a ΔΔGFoldX ≥ 0 kcal/mol (ΔΔGFoldX = ΔGmut 
– ΔGwt) (Figure 4-1). All of the mutants (n = 92) that had a ΔΔGFoldX ≤ -1 kcal/mol 
were visually inspected, resulting in the elimination of another 61 mutants that appear 
to modify the PlyC structure in an unfavorable manner. Examples of these 
disadvantageous structure changes are disruption of salt-bridge and dipole 
interactions, replacement of salt-bridge interactions with weaker dipole interactions, 
generation of cavities in the hydrophobic core by the introduction of an amino acid 
with a smaller side-chain, exposure of hydrophobic side-chains at the surface, and 









Figure 4-1. Log distribution of the predicted change in folding free energy 
(ΔΔGFoldX) for all 2,945 possible PlyCA CHAP domain point mutants calculated with 
FoldX 3.0 PositionScan. Mutations with ΔΔGFoldX < 0 are expected to increase protein 















Table 4-1. List of the final 10 PlyC mutant candidates, including the specific 
mutation (column 1), the location of the mutation within the CHAP domain of PlyCA 
(column 2) and the calculated ΔΔG (kcal/mol) values by the FoldX (column 3) or 









Wild-type -------- -------- -------- 
D330Y Surface, near the active site -1.09 -2.51 
Q332H Surface, near the active site -2.19 0.01 
Q332V Surface, near the active site -1.79 -1.29 
C345T Surface with potential domain-domain interaction -1.20 -2.70 
D375Y Surface with potential domain-domain interaction -2.49 -1.53 
T381Y Surface with potential domain-domain interaction -1.32 -2.65 
V384Y Surface with potential intra-domain hydrogen bond -1.04 -5.57 
C404I Hydrophobic core -2.17 -5.44 
T406R Surface with potential domain-domain interaction -1.05 -1.29 
T421I Hydrophobic core, near the active site -2.38 -3.43 
 
The impact of the mutations encoded by the remaining 31 mutants was analyzed by 
the Rosetta ddg monomer algorithm (Kellogg et al., 2011) to further evaluate likely 
stabilizing potential (Figure 4-2). Rosetta predicted 12 of the 31 mutants to be 
destabilizing (ΔΔGRosetta > 0.01 kcal/mol) and these were eliminated from further 
consideration (Figure 4-2, triangles). An additional mutant, PlyC (PlyCA) Q332H, 
has a predicted mildly destabilizing ΔΔGRosetta of 0.01 kcal/mol, but was retained 
since it is in an interesting location, adjacent to the active site cysteine of the CHAP 
domain, C333. Although mutations near the active site generally induce activity 





overall thermal stability (Daude, Topham, Remaud-Simeon, & Andre, 2013; Kamal, 
Mohammad, Krishnamoorthy, & Rao, 2012; Kanaya, Oobatake, & Liu, 1996; Lam, 
Yeung, Yu, Sze, & Wong, 2011; Xie et al., 2014; Zhi, Srere, & Evans, 1991). In 
addition to Q332H, the PlyC (PlyCA) mutants D330Y, Q332V, C345T, D375Y, 
T381Y, V384Y, C404I, T406R and T421I were also selected as candidates for 
experimental study, on the basis of predicted ΔΔG < 0 kcal/mol by both of FoldX and 
Rosetta (Figure 4-2, diamonds, Table 4-1). These final 10 candidates consisted of 
mutations located near the CHAP domain active site (D330Y, Q332H, Q332V), in the 
hydrophobic core (C404I and T421I), and at the surface predicted to form an intra-
domain hydrogen bond (V384Y) or an inter-domain interaction with the N-terminal 
GyH domain (C345T, D375Y, T381Y, T406R). The other nine mutants with FoldX 
and Rosetta ΔΔG < 0 kcal/mol values were omitted from further characterization 
(Figure 4-2, circles). These had similar structural locations to those selected, and were 
hypothesized to employ analogous stabilizing mechanisms so that inclusion would 
not improve the diversity of the candidate pool.  
 
Figure 4-2. Comparison between the ΔΔGFoldX and ΔΔGRosetta values of the final 31 
mutant candidates retained after manual curation. Twelve of these remaining mutants 
displayed a ΔΔGRosetta > 0.01 kcal/mol and were not further considered (triangles).  Of 
the remaining 19 mutants (circles and diamonds), 10 were selected for experimental 
characterization (diamonds). All of the final candidates had predicted ΔΔG ≤ 0.01 








(Figure 4-2, See above for caption) 
 
4.4.1 Protein Solubility, Purity and Secondary Structure Determination 
PlyC (PlyCA) mutants Q332H, Q332V, C345T, D375Y, V384Y, C404I and T406R 
all expressed as soluble holoenzymes and were purified to homogeneity based on 
SDS-PAGE analysis (Figure 4-3). No protein expression was observed for PlyC 
(PlyCA) D330Y and T381Y and therefore both were excluded from further 
characterization (data not shown). SDS-PAGE and far-UV CD secondary structure 
analysis of purified PlyC (PlyCA) T421I showed a mixed population of holoenzyme 
and uncomplexed PlyCB octamer structures (data not shown). To overcome this 
issue, a C-terminal 6x His-tag was added to PlyCA T421I. This mutant was expressed 
and purified in the same manner as the other PlyC mutants, with two alterations; 





a final immobilized metal affinity chromatography (IMAC) step using a 5 ml Bio-
Scale Mini Profinity IMAC Cartridge (Bio-Rad) to remove uncomplexed PlyCB 
octamers.  
 
Protein secondary structure analysis was performed using far-UV CD. The CD 
spectra for all of the proteins analyzed were represented in terms of mean residue 
ellipticity (MRE) as a function of wavelength (Figure 4-4a). All eight of the purified 
PlyC mutants displayed no deviation in secondary structure when compared to that of 
wild-type. The far-UV spectra resembles that of an α/β folded protein, displaying 
ellipticity minima at 208 nm and 220 nm, and ellipticity maxima at 195 nm 
(Greenfield & Fasman, 1969; Kelly, Jess, & Price, 2005). Secondary structure 
composition analysis results depict highly homologous regular α-helical (±1.1%), 
distorted α-helical (±1.2%), regular β-strand (±1.0%), distorted β-strand (±0.5%), turn 
(±0.7%) and unordered (±0.7%) structures when comparing wild-type to the eight 
point mutants (data not shown). The normalized root mean square deviation 
(NRMSD) value, which measures the goodness-of-fit between back-calculated 
spectra (spectra extrapolated using the CONTIN method for soluble proteins with 
known crystal structures) and experimental spectra, for each sample was < 0.1, 
suggesting the back-calculated and experimental spectra are in close agreement. Thus, 
none of the point mutations introduced significantly affected the secondary structure 











Figure 4-3. SDS-PAGE analysis of the various PlyC constructs experimentally 
characterized. The solubility and purity of each enzyme was analyzed on a 4-15% 
gradient SDS-PAGE gel. The various lanes correlate to: (M) Molecular weight 
standard, (1) Wild-type, (2) PlyC (PlyCA) Q332H, (3) Q332V, (4) C345T, (5) 
D375Y, (6) V384Y, (7) C404I, (8) T406R and (9) T421I. Protein expression was not 
observed for PlyC (PlyCA) D330Y and T381Y and therefore both were excluded 


















Figure 4-4. Secondary structure and thermal stability determination. (a) The 
secondary structure of each of the PlyC construct was analyzed by far-UV CD 
spectroscopy from 190-260 nm. The mean residue ellipticity [θ] (deg cm2 dmol-1) was 
plotted against wavelength (nm) for each mutant, with all of the resulting spectra 
being overlaid for comparative purposes. The thermal stability of each mutant was 
then analyzed by means of (b) CD thermal denaturation and (c) DSC experiments in 
20 mM phosphate buffer, pH 7.0, at a protein concentration of 1 mg/ml using a 
heating rate of 1°C/min. Note, only data for PlyCA is depicted for CD and DSC 










4.4.2 Kinetic Analysis of Bacteriolytic Activity against S. pyogenes 
To assess the bacteriolytic activity of each PlyC mutant, the purified enzymes were 
incubated with S. pyogenes D471 at different molar concentrations and the resulting 
activity was elucidated by turbidity reduction assays. There were no activity defects 
observed with the PlyC (PlyCA) C345T, D375Y and V384Y mutants, displaying 
1.13, 1.03 and 1.23 fold increases in activity when compared to wild-type, 
respectively (Table 4-2).  PlyC (PlyCA) mutants C404I and T406R exhibited a 
moderate loss in activity, exhibiting a respective 2.2 and 2.1 fold decrease in activity.  
More significant activity deficiencies were observed with the PlyC (PlyCA) Q332H, 
Q332V and T421I mutants, of 3.6, 9.1 and 16.7 fold reduction in activity, 
respectively. 
 
Table 4-2. Bacteriolytic activity quantitation by means of S. pyogenes turbidity 








Wild-type 45350 1.00 
Q332H 12730 0.28 
Q332V 4950 0.11 
C345T 51180 1.13 
D375Y 46550 1.03 
V384Y 55560 1.23 
C404I 16000 0.45 
T406R 21550 0.48 






4.4.3 Circular Dichroism Thermal Stability Analysis 
Equal molar concentrations of the PlyC mutant enzymes were subjected to CD 
thermal denaturation experiments to determine the TG values of the mutagenized 
PlyCA subunits in the context of the holoenzyme structure (Figure 4-4b). Over the 
temperature range tested, distinct thermally-induced structural transitions were 
observed for both the PlyCA and PlyCB subunits for each mutant analyzed. When 
monitoring the loss of α-helical secondary structure, PlyCA qualitatively exhibits a 
single, cooperative structural transition that is not reversed on cooling. PlyC (PlyCA) 
mutations Q332V, C345T, D375Y, C404I and T421I were destabilizing, decreasing 
the TG of the catalytic subunit by 1.98°C, 0.07°C, 2.45°C, 0.99°C and 10.41°C, 
respectively, when compared to wild-type (TG = 50.09°C) (Table 4-3). The PlyC 
(PlyCA) mutants Q332H and V384Y slightly stabilized PlyCA by 0.08°C and 
0.39°C, respectively. The T406R point mutation to the catalytic subunit of PlyC was 












Table 4-3. Biophysical thermal analysis of wild-type PlyC and the computationally 
predicted stabilizing point mutants. Results from CD thermal denaturation (columns 2 




Circular Dichroism  Differential Scanning Calorimetry 
TG (°C) ΔTG (°C) 
 







Wild-type 50.09 -  48.27 50.67  171.23 205.09  
Q332H 50.17 +0.08  48.47 50.74  177.07 211.87  
Q332V 48.11 -1.98  46.94 49.28  150.50 192.22  
C345T 50.02 -0.07  48.00 50.45 55.56 158.39 205.09 193.50 
D375Y 47.64 -2.45  46.26 48.78  156.01 181.05  
V384Y 50.48 +0.39  48.50 50.79 57.05 173.96 212.65 252.90 
C404I 49.10 -0.99  47.72 49.99  153.76 203.14  
T406R 52.36 +2.27  50.48 53.05  192.68 211.38  
T421I 39.68 -10.41  39.24 45.75 49.64 121.37 113.83 118.01 
 
 
4.4.4 Differential Scanning Calorimetry 
To validate the CD structural stability analysis, the thermal denaturation of each PlyC 
mutant was investigated by DSC at equal molar concentrations (Figure 4-4c). 
Thermal transitions corresponding to the unfolding of both the PlyCA and PlyCB 
components of the holoenzyme were observed for each mutant inspected. DSC 
analysis of the FoldX mutants depicts PlyCA unfolding to fulfill a three-state, and in 
some cases, four-state, thermal transition model. Heating the protein samples from 
15°C to 105°C followed by immediate cooling from 105°C to 15°C did not result in 







Consistent with CD results, PlyC (PlyCA) mutants Q332V, C345T, D375Y, C404I 
and T421I were less thermostable than wild-type (TG = 48.27°C, van’t Hoff enthalpy 
of unfolding (ΔHVH) = 171.23 kcal/mol) when analyzed by DSC, encompassing a 
1.33°C, 0.27°C, 2.01°C, 0.52°C and 9.03°C decrease in PlyCA TG and a 20.73 
kcal/mol, 12.84 kcal/mol, 15.22 kcal/mol, 17.47 kcal/mol and 49.86 kcal/mol 
reduction in ΔHVH, respectively (Table 4-3). PlyC (PlyCA) mutants Q332H and 
V384Y displayed marginable increases in stability, with an increase in PlyCA TG of 
0.20°C and 0.23°C, and a 5.84 kcal/mol and 2.73 kcal/mol gain in ΔHVH , 
respectively. The T406R mutation produces a more notable improvement in the 
thermal fitness of PlyCA, improving the TG and ΔHVH by 2.21°C and a 21.45 
kcal/mol, respectively. 
 
4.4.5 45°C Kinetic Inactivation Analysis 
The rate of thermally-induced kinetic inactivation was monitored for wild-type PlyC 
and the lead FoldX mutant candidate, PlyC (PlyCA) T406R, at 45°C for a total of 3 
hours. For this particular assay, the unfolding of PlyCA is directly correlated with the 
loss of bacteriolytic activity as a function of temperature and time. The loss in activity 
is not associated with the unfolding of the PlyCB binding domain of PlyC due to the 
inherent thermal stability of the octameric CBD complex of the CBD. The heat-labile 
nature of wild-type PlyC promoted rapid PlyCA unfolding at 45°C, resulting in a 
half-life (t1/2) of 17.84 min (Figure 4-5, squares). Conversely, PlyC (PlyCA) T406R 





wild-type, displaying an extrapolated t1/2 increase to 286.09 minutes (Figure 4-5, 
inverted triangles).  
 
Figure 4-5. Kinetic stability of wild-type PlyC and PlyC (PlyCA) T406R at 45°C. 
Equal molar concentrations of wild-type PlyC and PlyC (PlyCA) T406R were 
incubated at 45°C for a total of 3 hours. At 20 minute increments, the residual lytic 
activity of each enzyme was monitored by means of turbidity reduction assay. The 
activity of each was normalized to the lytic activity displayed by the unheated sample. 








Nineteen of the final 31 FoldX mutants were validated by Rosetta to be stabilizing, 
with the other 12 mutations calculated to be energetically unfavorable. Similar to 
FoldX, Rosetta appeared to favor mutations at the polar regions of the CHAP domain, 
with 12 of the predicted 19 advantageous point mutations being located at the surface. 
However, the percentage of the predicted stabilizing mutations located at the surface 
versus the hydrophobic core seems to be more evenly distributed for Rosetta (63% 
versus 37%) than FoldX (74% versus 26%). Additionally, the number of favorable 
mutations predicted to be near the active site was decidedly higher using FoldX 
(42%) than Rosetta (26%).   
 
A final top ten candidate list, which was assembled based on the most favorable ΔΔG 
values independently validated by the FoldX and Rosetta algorithms, was 
experimentally analyzed. Due to an absence of protein expression, two of the ten 
candidates were immediately eliminated from further characterization. Of the eight 
experimentally characterized PlyC point mutants, only three of the mutations were 
found to be thermostabilizing (Figure 4-4b and c, Table 4-3). Both of the mutations to 
the hydrophobic core region of the CHAP domain were unfavorable, while three of 
the six surface mutations increased the stability of PlyCA. Of the three stabilizing 
mutations, the two mutations distant from the active site of CHAP gave the largest 
improvements in thermal stability. There was no correlation between the magnitude 
of the ΔΔG values estimated by the FoldX and Rosetta algorithms and the 





mutant that exhibited the greatest gain in stability, PlyC (PlyCA) T406R, was 
predicted to be the second least favorable mutation of the eight experimentally tested 
by both FoldX and Rosetta. Conversely, despite possessing the second most 
stabilizing ΔΔG value calculated by both algorithms, the PlyC (PlyCA) T421I mutant 
displayed the highest degree of thermolability of the eight mutants thermally 
characterized. 
 
With respect to the effectiveness of the FoldX and Rosetta algorithms for estimating 
CHAP domain mutant ΔΔG values, it should be born in mind that these calculations 
are based on a relatively low-resolution 3.3-Å X-ray crystal structure that is highly 
complex and dynamic. Computationally modeling mutations into an intricate nine-
subunit holoenzyme structure with incomplete atomic coordinates and a flexible 
catalytic subunit could contribute to the inconsistency between the computational and 
experimental data. In addition, there are many approximations in the computational 
methods, and neither adequately treats contributions from altered dynamics resulting 
from the mutations. Thus the low correlation between predicted and observed effects 
on thermostability is not surprising. Nevertheless, the ΔΔG estimates derived from 
FoldX ultimately did yield one very useful and non-obvious candidate that increased 
the stability of PlyCA, at the expense of some extra experimental work on non-useful 
ones.  There may, of course, be other potentially useful mutations that the procedure 






Although the structural integrity of all eight of the remaining PlyC mutants remained 
intact (Figure 4-3 and Figure 4-4a), endolysin turbidity reduction activity titers 
showed that while the C404I and T406R mutations respectively caused considerable 
2.2 and 2.1 fold decreases in activity, the Q332H, Q332V and T421I mutations to the 
CHAP domain generated significant activity defects that correlated to 3.6-16.7 fold 
losses in activity (Table 4-2). Considering the PlyCA CHAP domain has active site 
residues at C333 and H420 (Nelson et al., 2006), it was not surprising to observe 
major perturbations to the catalytic efficiency of the enzyme when introducing amino 
acid mutations adjacent to either of the two active site residues. Of the five point 
mutations that conferred a loss in bacteriolytic activity, four of these mutations were 
located in the hydrophobic core and/or near the active site of the CHAP domain. 
There is no correlation between the activity displayed by a particular PlyC construct 
and the extent of its predicted ΔΔG values by either FoldX or Rosetta.  
 
After being subjected to a biophysical thermal analysis, the lead mutant candidate 
was PlyC (PlyCA) T406R, which displayed a ~2.2°C increase in PlyCA thermal 
denaturation temperature with a 21.45 kcal/mol gain in ΔHVH (Figure 4-4b and 4-4c, 
Table 4-3). The T406R mutation is located on the CHAP domain surface and is 
hypothesized to promote an inter-domain interaction between the N- and C-terminal 
domains of the PlyCA subunit. Modeling the T406R mutation into the CHAP domain 
shows how the elongated arginine side-chain allows the formation of a stabilizing 
hydrogen bond with the polar Q106 side-chain located on the surface of the N-





domain interaction engineered by the T406R mutation also resulted in an increase in 
kinetic fitness, with the point mutant promoting an extrapolated 16 fold augmentation 
in kinetic stability at 45°C (Figure 4-5). Although PlyC (PlyCA) T406R had an 
overall reduction in bacteriolytic activity when compared to the endogenous activity 
of wild-type PlyC, a common observation when thermostabilizing biomolecules 
(Arnold, Wintrode, Miyazaki, & Gershenson, 2001; Beadle & Shoichet, 2002; Giver, 
Gershenson, Freskgard, & Arnold, 1998; Meiering, Serrano, & Fersht, 1992; 
Mukaiyama et al., 2006; Shoichet, Baase, Kuroki, & Matthews, 1995; Yutani, 
Ogasahara, Tsujita, & Sugino, 1987), the residual activity displayed by the mutant 
nonetheless remains more potent than that of any other characterized endolysin.  
 
It is important to keep in mind that, although the ~2.2°C increase in thermal 
denaturation temperature displayed by the PlyC (PlyCA) T406R mutant was modest, 
this mutation provoked a pronounced 16 fold improvement in kinetic stability. 
Moreover, engineering significantly enhanced thermal stability to proteins is 
generally achieved through combining multiple thermostabilizing amino acid 
mutations that individually have a small effect on stability (Akasako, Haruki, 
Oobatake, & Kanaya, 1995; Ohage & Steipe, 1999; Pantoliano et al., 1989; Serrano, 
Day, & Fersht, 1993; Shih & Kirsch, 1995; von der Osten et al., 1993). If the 
mechanism of stabilization employed by each individual mutation is unique, then 
combining these advantageous mutations can additively stabilize the protein. To this 





(Q332H, V384Y, T406R) could be combined to possibly further progress the thermal 
properties of PlyC.  
Figure 4-6. Local structure around wild-type PlyCA T406 with the proposed 
conformation of the mutant T406R superimposed. The crystal structure of the wild-
type PlyCA T406 residue (blue sticks) and the model of the PlyCA mutant residue 
T406R (green sticks) are shown together with the surrounding residues. The predicted 
additional hydrogen bond between Q106 of the N-terminal GyH domain and R406 of 
the C-terminal CHAP domain is shown as orange dots. Parts of the polypeptide 
backbone of the PlyCA N-terminal GyH domain (magenta) and the C-terminal CHAP 
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Chapter 5:  Conclusion and perspectives 
 
In this dissertation, I used various computational methods to analyze and predict the 
molecular, phenotypic, and pathogenic effects of missense mutations. In the last 
chapter, I briefly summarize the conclusions of each project and look to the future in 
these fields. 
 
5.1 Brief summary 
In the first project, I developed a new ensemble approach to address a largely 
unsolved mutation interpretation problem – predicting continuous phenotype values, 
in one case for the enzyme activity of a set of rare human mutations in a monogenic 
disease gene and in the other for a yeast complementation growth assay for mutations 
of human SUMO-ligase. The ensemble approach was relatively effective for this task, 
as well as for regular binary pathogenicity assignments. In addition, I investigated the 
potential of the ensemble method in estimating the reliability of pathogenicity 
assignments for better clinical applicability. Next, I characterized and compared the 
mutations in monogenic disease and in cancer, looking for the unique features of 
cancer driver mutations and directions to improve current mutation interpretation 
methods on cancer data. The results pinpointed the issue of passenger mutations in 
cancer driver genes and confirmed the applicability of general interpretation methods 
and properties of mutations for three structure related protein features. Finally, I 





mutation effects on protein stability. Experiments by our collaborators showed 
encouraging success, although significant improvements can be made in several 
aspects of that task, as discussed below. 
 
5.2 The demand for the right dataset 
Methods to interpret mutation effects in monogenic diseases and complex trait 
diseases often rely on training datasets that comprises a case set of disease-related 
mutations collected from literature or curated databases such as HGMD (Stenson et 
al., 2014), UniProt (UniProt consortium 2015), OMIM (http://omim.org/), and 
ClinVar (Landrum et al., 2016), and a control set of neutral mutations obtained from 
observed variants across species or polymorphisms in populations. The computational 
methods developed based on these datasets are mostly designed to make a binary 
assignment of pathogenic or nonpathogenic, and have been benchmarked in many 
studies (Dong et al., 2015; Gnad et al., 2013; Thusberg, Olatubosun, & Vihinen, 
2011). It was less clear how these methods perform on more realistic datasets such as 
in the CAGI NAGLU challenge (Hoskins et al., 2017), where mutation effects are 
distributed more evenly across the entire range of functional activity.  Mutations with 
a mid-range molecular or functional effects still pose a challenge for all contemporary 
approaches. To fully investigate this issue, there is a major requirement for more 
realistic training and testing datasets like NAGLU. However, one impediment is to 







The advent of high-throughput techniques such as deep mutational scanning in the 
last several years provides a potential solution to this. Like in the CAGI SUMO-ligase 
challenge, these techniques are able to measure the functional consequences of 
thousands of mutants, together with massive sequencing to identify corresponding 
mutations (Fowler & Fields, 2014; Wrenbeck, Faber, & Whitehead, 2017). On the 
other hand, there are inherent limitations to these techniques. I investigated the 
performance of an ensemble method on a set of deep mutational scanning datasets 
and found poorer results than on more traditional single measurement datasets. 
Potential issues include data quality and stochastic error (Fowler & Fields, 2014). 
This issue needs to be addressed more thoroughly and rigorously, for example with 
the statistical framework proposed recently (Rubin et al., 2017). Moreover, deep 
mutational scans are usually implemented in the growth-based assay, phage display or 
cell flow sorting, which are only capable of measuring a limited set of phenotypes. In 
the SUMO-ligase challenge, another possible complication is that the interfaces 
between human SUMO-ligase and its binding partners in human and in yeast may 
have different properties. Nevertheless, the high-throughput techniques will help 
provide more valuable data for mutation effect analysis in the future. 
 
In both the NAGLU and SUMO-ligase challenges, a potential cause of apparent false 
positive predictions arises from the use of cDNA constructs in the experiments. As a 
result, those missense mutations that affect splicing or alter the ratio of alternatively 
spliced isoforms in vivo (D’Souza et al., 1999; Ward & Cooper, 2009) would not 





overlap of missense mutations with bases critical to splicing and found none. 
However, effects on splice enhancers and silencers (D’Souza et al., 1999; Ward & 
Cooper, 2009) are less straightforward to detect, and these may contribute false 
positives. 
 
In the analyses of both monogenic disease and cancer, the negative control dataset 
was compiled using interspecies variants, that is amino acid differences in other 
species compared to human, assuming these substitutions would be benign in the 
human protein. However, it has been estimated that, on average, around 10% of these 
interspecies variants could be pathogenic to humans, but benign to other species due 
to compensation by substitutions at other sites (Kondrashov, Sunyaev, & 
Kondrashov, 2002). This issue was reduced in our analysis by excluding known 
human pathogenic mutations from the observed interspecies variants. A more 
sophisticated approach would be to examine all coevolving sites in the sequence 
profile of the homolog proteins and their potential interacting partners. 
 
In the past decade, cancer research has greatly benefited from the explosion of cancer 
whole genome and exome sequencing data. The accuracy of many driver gene 
predictions depends on these large-scale data. On the other hand, interpreting and 
identifying the few cancer driver mutations in individuals creates a demand for a 
large gold standard dataset of the experimentally verified driver and passenger 





the ICGC’s Pan-Cancer Analysis of Whole Genomes (PCAWG) 
(https://dcc.icgc.org/pcawg). 
 
For both complex trait disease and cancer, there is also a significant contribution from 
non-coding mutations. Generating large datasets in this regard is a new hotspot of 
research, and has been undertaken with great energy (GTEx Consortium et al., 2017; 
X. Li et al., 2017). New methods utilizing these datasets are now under development. 
 
5.3 Improving mutation interpreting methods 
A lesson learned from the CAGI NAGLU and SUMO-ligase challenges is that no 
contemporary mutation interpretation method provides revolutionary accuracy in 
predicting the experimental activity values. This suggests inherent deficiencies in the 
current prediction models that primarily relate sequence conservation patterns to 
pathogenicity. There are a number of ways in which more realistic evolutionary 
information could be utilized to provide potential improvements. These include the 
better utilization of phylogenetic information and incorporation of the relative 
likelihood of particular mutation types such single versus double base changes, 
transition/transversion relative frequencies and CpG island hotspots. 
 
As noted earlier, most current methods produce binary predictions of pathogenic or 





desirable. My ensemble approach, combining confidence scores for binary methods, 
provides one solution to this problem. It would also be interesting to explore methods 
that directly predict a continuous value. One approach would be to use appropriate 
machine learning methods, such as support vector regression. 
 
A few contemporary methods also partially or fully rely on protein structure 
information. These methods can be improved by including state of the art structure 
modeling methods that take into account backbone flexibility and extensive rotamer 
optimization, such as ROSETTA (B Kuhlman & Baker, 2000; Rohl et al., 2004). 
Current models mainly focus on the destabilizing effect of mutations, which plays an 
important role in human diseases (Casadio, Vassura, Tiwari, Fariselli, & Luigi 
Martelli, 2011; Redler et al., 2016; Shi & Moult, 2011; Yue et al., 2005). However, 
the effects of some mutations, especially in cancer oncogenes where more driver 
mutations are located on the protein surface, manifest under various mechanisms such 
as catalytic activity, specificity, binding affinity and protein flexibility. While 
modeling on some of these are still challenging, molecular dynamics techniques 
provide a potential solution to tackle the modeling problems such as in intrinsically 
disordered regions and at the protein-macromolecular interfaces (Agarwal, 
Annamalai, Maiti, & Arsad, 2016; Doss, Chakraborty, Chen, & Zhu, 2014; George 






Additional improvement of methods may also come from 1) differentially treating 
mutations subsets, such as surface and core mutations, 2) retraining models on the 
mutations where methods do not correlate well, 3) developing gene-specific models, 
and 4) better frameworks that integrate sequence conservation-based methods with 
structure-based methods. 
 
5.4 Bridging the gap between mutation research and clinical application 
In the first project of this dissertation, I investigated the potential of ensemble 
methods to estimate the reliability for pathogenicity assignments, which is important 
in clinical applications because an accurate method may still fail on a certain subset 
of mutations. So far, this issue has not been well investigated. As a consequent, 
present clinical guidelines treat computational interpretation of potential disease 
mutations as only secondary evidence of a genetic cause (Richards et al., 2015). The 
ensemble methods achieved a substantial fraction (up to 40%) of pathogenicity 
assignments with clinically meaningful confidence (>90%). Future work and more 
testing on more data in various diseases will help increase the clinical applicability. 
 
A large set of cancer driver genes have been prioritized from examination of large-
scale cancer whole genome and exome data. A clinically more relevant task is to 
identify all driver mutations given a single cancer genome or exome. This creates a 
demand for methods to identify a long tail of potential driver genes with rare driver 





continuous cancer driver mutation penetrance instead of the current binary ‘driver vs. 
passenger’ model. 
 
5.5 Beyond simple approaches for protein thermostability engineering 
The T406R mutation we identified in the PlyCA CHAP domain (Heselpoth, Yin, 
Moult, & Nelson, 2015) displayed limited improvement in thermal stability, typical of 
that achievable with single mutations. Achieving a large improvement in stability 
usually requires a combination of multiple stabilizing mutations that operate in an 
additive or non-addition manner. On the other hand, the low success rate (3 out of 10) 
of our method reflects the serious false positive problem. Potential causes include but 
are not limited to the low-quality modeling from template structures, use of a rigid 
backbone protocol in structure modeling, and not including more structure modeling 
methods that can provide a consensus set of candidates. A recent work (Goldenzweig 
et al., 2016) reported a significant success in engineering thermally stable mutants (a 
20C increase in denaturation temperature), based on a strategy that combined 
searching for multiple stabilizing mutations with a method to remove false positives 
using phylogeny information. In future, one would expect this type of strategy to be 
more common. Indeed, our collaborator found a higher thermostability when 
combined T406R with another stabilizing mutation previously identified through a 
directed evolution approach. Computational methods also have the potential to 
engineer for thermostability in a broader range of conditions, such as altered pH 






Another issue with the successful T406R mutation was that it has a cost of more than 
half catalytic activity, as observed for many stabilizing mutations (Arnold et al., 
2001; Beadle & Shoichet, 2002; Mukaiyama et al., 2006). It is still challenging to 
rationally model mutation effects in the context of enzyme activity that involves 
complicated physical-chemical calculation of the transition state complex. Enzyme 
activity may also be affected by changes in protein flexibility and dynamics. Such 
issues can be addressed by better integrating results of molecular dynamics methods 
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